<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2312211501
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEPATIER 100/50 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GRAZOPREVIR,ELBASVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        49171.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AP54
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zepatier is</strong></p><p>Zepatier is an antiviral medicine that contains the active substances elbasvir and grazoprevir.</p><p>&nbsp;</p><p><strong>What Zepatier is used for</strong></p><p>Zepatier<strong> </strong>is used to treat long-term hepatitis C infection in adults aged 18 years and older.</p><p>&nbsp;</p><p>How Zepatier work</p><p>Hepatitis C is a virus that infects the liver. The active substances in the medicine work together by blocking two different proteins that the hepatitis C virus needs to grow and reproduce. This allows the infection to be permanently removed from the body.</p><p>&nbsp;</p><p>Zepatier is sometimes taken with another medicine, ribavirin.</p><p>It is very important that you also read the leaflets for the other medicines that you will be taking with Zepatier. If you have any questions about your medicines, please ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take ZEPATIER if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to elbasvir, grazoprevir or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have certain moderate or severe liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking any of the following medicines:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, usually given for tuberculosis</p><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HIV protease inhibitors such as atazanavir, darunavir, lopinavir, saquinavir, or tipranavir</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz or etravirine for HIV</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin to stop organ transplant rejection or to treat serious inflammatory illnesses of eyes, kidney, joints or skin</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan for pulmonary arterial hypertension</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine or phenytoin, mainly used for epilepsy and seizures</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil to help people who cannot stay awake</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>, a herbal medicine) for depression or other problems</p><p>&nbsp;</p><p>If you are taking ZEPATIER with ribavirin, please make sure that you read the &quot;Do not take&quot; section of the ribavirin package leaflet. If you are unsure of any information in the package leaflet, please contact your doctor or pharmacist.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking ZEPATIER if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a current or previous infection with the hepatitis B virus, since your doctor may want to monitor you more closely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever taken any medicine for hepatitis C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any liver problems other than hepatitis C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a liver transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medication after starting ZEPATIER. Some diabetic patients have experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like ZEPATIER.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any other medical conditions.</p><p>&nbsp;</p><p>Blood tests</p><p>Your doctor will test your blood before, during and after your treatment with ZEPATIER. This is so your doctor can:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decide if you should take ZEPATIER and for how long</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decide what other medicines you should take with ZEPATIER and for how long</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check for side effects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check if your treatment has worked and you are free of hepatitis C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check how your liver is working - tell your doctor straight away if you have any of the following signs of liver problems: loss of appetite; feeling or being sick; feeling tired or weak; yellowing of your skin or eyes; colour changes in your stool. Your doctor may want to test your blood to check how your liver is working if you develop any of these symptoms.</p><p>&nbsp;</p><p>Children</p><p>ZEPATIER is not for use in children younger than 12 years of age.</p><p>&nbsp;</p><p>Other medicines and ZEPATIER</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and medicines obtained without a prescription. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p><p>&nbsp;</p><p>There are some medicines you <strong>must</strong><strong> </strong><strong>not</strong><strong> </strong><strong>take</strong><strong> </strong>with ZEPATIER. See list under &ldquo;Do not take</p><p>ZEPATIER if you are taking any of the following medicines.&rdquo;</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you take any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral ketoconazole for fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus to prevent organ transplant rejection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabigatran to prevent blood clots</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rosuvastatin, atorvastatin, fluvastatin, simvastatin, or lovastatin, for lowering blood cholesterol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sunitinib to treat certain cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin and other similar medicines called vitamin K antagonists used to thin the blood. Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.</p><p>&nbsp;</p><p>Your liver function may improve with treatment of hepatitis C and therefore may affect other medications that are handled by the liver. Your doctor may need to closely monitor these other medicines you are taking and make adjustments during ZEPATIER therapy.</p><p>&nbsp;</p><p>Your doctor may have to change your medicines or change the dose of your medicines.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking ZEPATIER.</p><p>&nbsp;</p><p>Pregnancy and contraception</p><p>The effects of ZEPATIER in pregnancy are not known. If you are pregnant, think you might be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>ZEPATIER with ribavirin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not become pregnant if you are taking ZEPATIER with ribavirin. Ribavirin can be very damaging to an unborn baby. This means you and your partner must take special precautions in sexual activity if there is any chance you or your partner could become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your partner must use an effective method of contraception during treatment with</p><p>ZEPATIER with ribavirin and for some time afterwards. Talk to your doctor about different contraception methods that are suitable for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your partner becomes pregnant while taking ZEPATIER with ribavirin or in the</p><p>months that follow, tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important that you read the information concerning pregnancy and contraception in the ribavirin package leaflet very carefully. It is important that both men and women read the information.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Talk to your doctor before taking ZEPATIER if you are breast-feeding<strong>. </strong>It is not known whether the two medicines in ZEPATIER pass into human breast milk.</p><p>&nbsp;</p><p>If you are taking ZEPATIER with ribavirin, make sure that you also read the Pregnancy and Breast-feeding sections of the package leaflet for this other medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Do not drive or operate machines if you feel tired after taking your medicine.</p><p>&nbsp;</p><p>ZEPATIER contains lactose</p><p>ZEPATIER contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p><p>&nbsp;</p><p>ZEPATIER contains sodium</p><p>This medicine contains 69.85 mg sodium (main component of cooking / table salt) in each tablet. This is equivalent to 3.5% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Talk to your doctor or pharmacist before taking Zepatier<strong> </strong>if you have ever taken any medicines for hepatitis C or if you have any other medical condition.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose is one tablet once a day with or without food. Your doctor will tell you how many weeks you should take Zepatier for.</p><p>&nbsp;</p><p>Swallow the tablet whole with or without food. Do not chew, crush or split the tablet. Tell your doctor or pharmacist if you have problems swallowing tablets.</p><p>&nbsp;</p><p>If you take more Zepatier than you should</p><p>If you take &nbsp;more Zepatier than you should, &nbsp;talk to a doctor straight away. Take the medicine pack with you so that you can show the doctor what you have taken.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Zepatier</strong></p><p>It is important not to miss a dose of this medicine. If you do miss a dose, work out how long it is since you should have taken Zepatier:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If it has been less than 16 hours since you should have taken your dose, take the missed dose as soon as possible. Then take your next dose at your usual time.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If it has been more than 16 hours since you should have taken your dose, do not take the missed dose. Wait and take your next dose at your usual time.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not take a double dose (two doses together) to make up for a forgotten dose.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp; Do not stop taking Zepatier</strong><strong> </strong><strong>&nbsp;&nbsp;</strong></p><p>Do not stop taking this medicine unless your doctor tells you to. It is very important that you complete the full course of treatment. This will give the medicine the best chance to treat your hepatitis C infection.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine</p><p>Tell your doctor or pharmacist if you notice any of the following side effects.</p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling very tired (fatigue).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache.</p><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling sick (nausea).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling weak or lack of energy (asthenia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->itching</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhea</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->trouble sleeping (insomnia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->joint pain or painful, swollen joints.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->constipation</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling dizzy</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->loss of appetite.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling irritable .</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->muscle aches .</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stomach pain.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unusual hair loss or thinning.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling nervous (anxiety)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->depression</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dry mouth.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->being sick (vomiting).</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->abnormalities in laboratory tests of liver function</p><p>&nbsp;</p><p><strong>Reporting of Side Effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC) at SFDA. By reporting side effects, you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep this medicine out of the sight and reach of children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use the medicine after the expiry date which is stated on the carton and blister packaging after &lsquo;EXP&rsquo;. The expiry date &nbsp;is written in both carton&nbsp; &amp; blister.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store Zepatier<strong> </strong>below 30&deg;C. &nbsp;Protect from moisture.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zepatier contains</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>The active substances are</strong>: elbasvir and grazoprevir.</p><p>&nbsp;Each film-coated tablet contains 50 mg elbasvir and 100 mg grazoprevir.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>The other ingredients are:</strong></p><p><u>Tablet core: </u></p><p>colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, vitamin E polyethylene glycol succinate.</p><p><u>Film-coating: </u></p><p>carnauba wax, ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide and triacetin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The film-coated tablets are beige oval-shaped with the number 770 on one side and plain on the other. The tablet is 21 mm long and 10 mm wide. 
The tablets are packaged into a carton containing two cardboard cards, each cardboard card containing two 7-count aluminium blisters. Each carton contains a total of 28 tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder (MAH)</strong></p><p>Merck Sharp &amp; Dohme B.V.,</p><p>Waarderweg 39, 2031BN,</p><p>Haarlem, The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Shering-Plough Labo NV</p><p>Industriepark 30 &ndash; Zone A</p><p>B-2220 Heist-op-den-Berg</p><p>Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last Revised: Nov 2021


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to Instructions are dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>زيباتير هو علاج مضاد للفيروسات يحتوي على المادتين الفعالتين وهما: إيلباسفير، وجرازوبريفير.</p><p><strong>&nbsp;</strong></p><p><strong>ما</strong><strong> هي</strong><strong> </strong><strong>دواعي استعمال</strong><strong> زيباتير </strong></p><p>يستخدم دواء زيباتير لعلاج التهاب الكبد الفيروسي النّوع ج (سي) المزمن لدى الكبار من عمر 18 سنة فأكبر.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;كيف يعمل زيباتير</strong><br />الالتهاب الكبدي الفيروسي النوع ج (سي) هو فيروس يُسبب التهاب&nbsp; الكبد. تقومُ المادَّتانِ الفَعَّالَتَانِ &nbsp;بالعملِ معًا على تثبيط نوعين مختلفتين من البروتينات التي يحتاجها فيروس نوع ج (سي) للنمو والتكاثر. يسمح هذا بإزالة &nbsp;الفيروس بشكل دائم من جسد معظم الأفراد.</p><p>&nbsp;</p><p>في بعض الأحيان يتم تناول زيباتير مع دواء آخر، اسمه: ريبافيرين.</p><p>&nbsp;من المهم جدًّا أن تقرأ أيضا النشرة الداخلية للأدوية الأخرى التي سوف تتناولها مع زيباتير. إذا كان لديك أي أسئلة حول الأدوية الخاصة بك، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال</strong><strong> </strong><strong>زيباتير:</strong></p><p dir="RTL"><strong>&middot;&nbsp; </strong>إذا كنت تعاني من الحساسيّة&nbsp; لإيلباسفير أو جرازوبريفير أو أيّ من المكوّنات الأخرى في &nbsp;زيباتير .اقرأ البند 6</p><p dir="RTL"><strong>&middot;&nbsp; </strong>إذا كنت تعاني من مشاكل شديدة أو متوسطة بالكبد.</p><p dir="RTL"><strong>&middot;&nbsp; </strong>إذا كنت تتناول أيًّا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ريفامبيسين لعلاج مرض &nbsp;السُّلّ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزيم البروتيني لفيروس نقص المناعة المكتسبة مثل أتازانافير، دارونافير، لوبينافير، سيكوينافير، تيبرانافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرنز&nbsp; أو إيترافيرين &nbsp;لعلاج فيروس مرض نقص المناعة المكتسبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرنز/كوبيسيستات/امتريسيتابين/تنفوفير ديسوبروكسيل فيوماريت ، أو إيفافيرنز/كوبيسيستات/امتريسيتابين/تنفوفير ديسوبروكسيل الافيناميد لعلاج فيروس مرض نقص المناعة المكتسبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سيكلوسبورين&nbsp; لتثبيط رفض الجسم للأعضاء المزروعة أو لعلاج أمراض التهابات خطيرة في العيون أو الكلي أو المفاصل أو الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسينتان لعلاج إرتفاع ضغط الدم الشرياني الرئوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كارباميزابين &nbsp;أو فينوتوين &nbsp;لعلاج&nbsp; الصرع والتشنجات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مودافينيل لمساعدة الناس الذين لا يستطيعون البقاء مستيقظين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون ( دواء عشبي ) لعلاج الإكتئاب أو مشكلات أخرى.<br />&nbsp;</p><p dir="RTL">إذا كنت تتناول زيباتير مع ريبافيرين، تأكد من قراءة بند &quot;لا تتناول&quot; المذكور في النشرة الداخليّة لريبافيرين. إذا كنت غير متأكد من أي من المعلومات في النشرة ، اتصل بطبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المخاطر و الاحتياطات</strong></p><p dir="RTL"><strong>التحدث إلى طبيبك أو الصيدلي قبل تناول زيباتير إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك عدوى حالية او سابقة بفيروس التهاب الكبد الوبائي نوع ب، طبيبك سوف يتابعك بشكل مكثف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولتَ من قبل علاج لإلتهاب الكبد الوبائي الفيروسي النّوع ج (سي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتَ تعاني من مشكلات أخرى في الكبد عدا عن التهاب الكبد الوبائي النّوع ج (سي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعت لزراعة كبد في السابق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مرض السكري. قد تحتاج إلى مراقبة أدق لمستويات الجلوكوز في الدم و/أو تعديل علاج &nbsp;السكري الذ تتناوله بعد البدء بعلاج زيباتير. ولقد عانى بعض مرى &nbsp;السكري من إنخفاض مستويات السكر&nbsp; في الدم بعد بدء العلاج مع الادويه مثل زيباتير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل صحية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحاليل الدم</strong><br />سيقوم الطبيب بعمل تحاليل للدم قبل وأثناء وبعد العلاج بزيباتيير. و بالتالي يمكن لطبيبك:</p><ul><li dir="RTL">أن يقرر ما إذا كان يجب أن تتناول&nbsp; زيباتيير وإلى متى</li><li dir="RTL">أن يقرر ما الأدوية الأخرى التي يجب أن تتناولها&nbsp; مع زيباتيير وإلى متى</li><li dir="RTL">&nbsp;التحقق من الأعراض الجانبية</li><li dir="RTL">التحقق من نجاح علاجك وأنك خالِ من التهاب الكبد الوبائي الفيروسي النّوع ج (سي)</li><li dir="RTL">التحقق من كيفية عمل الكبد - أخبر طبيبك فورًا إذا كان لديك أي من الأعراض التالية من مشاكل في الكبد: فقدان الشهية؛ الشعور بالمرض، الشعور بالتعب أو الضعف. اصفرار الجلد أو العينين، تغير لون في البراز. قد يرغب طبيبك بعمل تحاليل للدم للتحقق من كفاءة عمل الكبد إذا كنت تعاني أي من هذه الأعراض.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">لا يستخدم زيباتيير في الأطفال الذين تقل أعمارهم عن 12 سنة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>زيباتيير</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، &nbsp;أو قد تناولت مؤخرًا أو قد تتناول أيّ أدوية أخرى. وهذا يشتمل على الأدوية العشبية والأدوية التي تم الحصول عليها دون وصفة طبية. احتفظ بقائمة الأدوية الخاصة بك، وأظهرها للطبيب والصيدلي عند الحصول على دواء جديد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وهناك بعض الأدوية التي لا يجب أن تتناولها مع زيباتير. انظر القائمة المذكوره أسفل &quot;لا تتناول زيباتير إذا كنت تتناول أي من الأدوية التالية&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلاني إذا كنت تتناول أيّ من الأدوية التالية:</strong></p><ul><li dir="RTL">كيتوكينازول عن طريق الفم لعلاج &nbsp;الالتهابات الفطرية.</li><li dir="RTL">تاكروليموس لتثبيط رفض الجسم للأعضاء المزروعة.</li><li dir="RTL">دابيجارتان لمنع تجلط الدم</li><li dir="RTL">روزوفاستاتين ، أتروفاستاتين ، فلوفاستاتين ، سيمفاستاتين ، أو لوفاستاتين لخفض مستوى الكولسترول في الدم</li><li dir="RTL">سنيتينيب ( لعلاج انواع من السرطان)</li><li dir="RTL">وارفارين وأدوية أخرى مشابهة تسمى مُضاد فيتامين &quot;ك&quot; يستخدم كمضاد لتجلط الدم. قد يحتاج الطبيب إلى زيادة تواتر اختبارات الدم الخاصة بك للتحقق من مدى تجلط الدم.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتحسن وظيفة الكبد مع علاج التهاب الكبد ج وبالتالي قد تؤثر على الأدوية الأخرى التي يتم التعامل معها من قبل الكبد. قد يحتاج طبيبك إلى مراقبة هذه الأدوية الأخرى التي تتناولها عن كثب وإجراء تعديلات أثناء علاج زيباتير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقوم الطبيب بتغيير الأدوية الخاصة بك أو تغيير جرعة الأدوية الخاصة بك. إذا كان أي من أعلاه ينطبق عليك (أو لم تكن متأكدًا)، تحدث إلى طبيبك أو الصيدلي قبل تناول زيباتير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل و موانع الحمل</strong></p><p dir="RTL">آثار زيباتير في الحمل غير معروفة. إذا كنتِ حاملًا، تعتقدين بأنك حاملٌ أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول زيباتيير مع ريبافيرين</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم حدوث حامل إذا كنتِ تتناولين زيباتير مع ريبافيرين. يمكن لريبافيرين أن يكون ضارًّا جدًّا للجنين. وهذا يعني أنه أنتِ و زوجك يجب أن تتخذا احتياطات خاصة في العلاقة الزوجية إذا كان هناك أي فرصة لحدوث حمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوجب عليكِ أنتِ أو شريكك استخدام وسيلة فعالة لمنع الحمل أثناء العلاج بدواء زيباتير مع ريبافيرين ولبعض الوقت بعد ذلك. تحدثي إلى طبيبك حول طرق منع الحمل المختلفة المناسبة لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري الطبيب مباشرة فور حدوث حمل أثناء تناول زيباتير مع ريبافيرين أو في الأشهر التي تليه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدًّا قراءة المعلومات المتعلقة بالحمل ووسائل منع الحمل في النشرة الداخلية لريبافيرين بعناية فائقة. من المهم أن يقوم الرجال وأيضّا النساء بقراءة تامة للمعلومات الخاصة بنشرة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنت ترضعين طفلك رضاعة طبيعية قبل تناول زيباتيير. ليس من المعروف إن كان زيباتير ينتقل إلى حليب الأم.</p><p dir="RTL">إذا كنتِ تتناولين زيباتير مع ريبافيرين، تأكدي من قراءة بند الحمل والرضاعة الطبيعية للأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا تَقُمْ بقيادة السيارة أو تشغيل الآلات إذا كنت تشعر بالتعب بعد تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زيباتيير على اللاكتوز </strong><br />يحتوي زيباتيير على مونوهيدرات اللاكتوز. &nbsp;إذا قيل لك من قبل الطبيب أنك تعاني من صعوبة في هضم بعض السكريات، تحدث إلى طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زيباتيير على والصوديوم</strong><br />يحتوي هذا الدواء على 69,85 ملغم من&nbsp; الصوديوم (مكون رئيسي لملح الطعام/الطبخ) في كل قرص. هذا يعادل 3.5 % من &nbsp;الحدالأقصى من الجرعة اليومية الموصى بها من الصوديوم للبالغين .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->&nbsp;&nbsp;تناول هذا الدواء&nbsp; تمامًا حسب ارشادات طبيبك أو الصيدلاني. تحقق من طبيبك أو الصيدلاني إذا لم تكن متاكدًا. تحدث الى طبيبك أو الصيدلاني قبل تناول زيباتيير إذا كنت قد تناولت في أي وقت مضى أي أدوية لإلتهاب الكبد الوبائي الفيروسي النوع ج (سي ). أو إذا كان لديك أي حالة طبية أخرى.</p><p><strong>&nbsp;</strong></p><p><strong>مقدار الجرعة </strong></p><p>الجرعة الموصى بها هي قرص واحد يوميًّا&nbsp; مع الطعام أو بدونه. سوف يبلغك الطبيب عن عدد الأسابيع التي يجب عليك أن تتناول فيها دواء زيباتير.</p><p>اِبتلع كامل القرص مع الطعام أو بدونه. لا تمضغ أو تسحق أو تقسم القرص. أخبر طبيبك أو الصيدلي إذا كان لديك مشاكل في بلع الأقراص.</p><p><br /><strong>في حال تناولت جرعة زائدة من زيباتير</strong><br />إذا تناولت جرعة زائدة من زيباتير، اتصل مع الطبيب على الفور، حتى لو لم يكن هناك أي أعراض. خُذ علبة الدواء معك حتى يمكن للطبيب أن يتحقق من عدد الأقراص التي تناولتها .<br /><br /><strong>في حال نسيت تناول جرعة زيباتير</strong><br />من المهم عدم نسيان تناول الجرعة من الدواء. في حال نسيان الجرعة، اعرف المدة منذ تناولت آخر جرعة من زيباتير.<br />&bull; إن كانت أقل من 16 ساعة منذ أن كان يجب عليك تناول هذه الجرعة، تناول الجرعة المنسية بأسرع ما يمكن، يتم تناول الجرعة التالية في الوقت المعتاد.<br />&bull; إن كان قد مَرَّ أكثر من 16 ساعة عن الوقت الذي كان يتعين عليك فيه استخدام الجرعة، لا تتناول الجرعة المنسية، انتظر حتى تتناول الجرعة التالية في الوقت المعتاد.<br />&bull; لا تتناول جرعة مزدوجة ( جرعتان سويًّا ) لتعويض الجرعة المنسيّة.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>لا تتوقف عن تناول زيباتير</strong></p><p>&nbsp;لا تتوقف عن تناول هذا الدواء ما لم يخبرك طبيبك بذلك. من المهم جدًّا إكمال دورة العلاج كاملة. وهذا سيعطي الدواء أفضل فرصة لعلاج عدوى التهاب الكبد الوبائي نوع ج &quot;سي&quot;.</p><p>إذا كان لديك أيّ أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.<br /><br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>على غرار جميع الأدوية، قد يسبب تناول هذا الدواء أعراضًا جانبية محتملة على الرغم من أنها قد لا تحدث لجميع الأشخاص. قد تحدث الأعراض الجانبية التالية عند تناول هذا الدواء.</p><p>أخبر طبيبك أو الصيدلي إذا لاحظت أي من الأعراض الجانبية التالية.</p><p>&nbsp;</p><p><strong>الشائعة جدًا: </strong>قد تؤثر على أكثر من شخص 1 لكل 10 أشخاص</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالتعب الشديد (الإعياء)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الصداع</p><p>&nbsp;</p><p><strong>الشائعة :</strong> قد تؤثر على شخص 1 لكل 10 أشخاص</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالمرض (الغثيان)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالضعف أو فقدان الطاقة (الوهن)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحكة</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسهال</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صعوبة في النوم</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->آلام المفاصل أو تورم المفاصل المؤلم.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإمساك</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الدوخة</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الشهية</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سرعة الانفعال</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في العضلات</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في البطن</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الشعر الغير اعتيادي أو خفة الشعر</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->القلق</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اكتئاب</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جفاف الفم</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->غثيان أو قيء</p><p><strong>&nbsp;</strong></p><p><strong>غير الشائعة :</strong> قد تؤثر على شخص 1 لكل 100 أشخاص</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اِضطراب في الفحوص المخبرية لوظائف الكبد</p><p><strong>&nbsp;</strong></p><p><strong>الإبلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p>اتّصل بالطبيب أو الصيدلي أو في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائيّة، التابع للهيئة العامة للغذاء والدواء بالمملكة العربية السعودية&quot;</p><p>&nbsp;يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبيّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية و الشريط بعد الرمز &quot;EXP&quot;. تاريخ انتهاء الصلاحية مذكور على العبوة الكرتونية والشريط.</p><p><!--[if !supportLists]--><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية. يُحفظ بعيدًا عن الرطوبة</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br /><strong>المادتان الفعالتان هما</strong> : إيلباسفير وجرازوبريفير<br />يحتوي كل قرص مغلف&nbsp; على 50 ملغم إيلباسفير و 100 ملغم &nbsp;جرازوبريفير</p><p><strong>المكونات الأخرى &nbsp;هي: </strong><br /><u>لُب القرص:</u></p><p>كولويدال سيلكا ثنائي الأكسيد ، كوبوفيدون،كروسكارميلوز الصوديوم، هبروميلوز، أحادي هيدرات اللاكتوز، ستيرات الماغنيسيوم، المانيتولول، ميكروكرستالين السيليلوز، كلوريد الصوديوم، سلفات لوريل الصوديوم ، فيتامين هـ ، بوليثيلين جلايكول سوسينات.</p><p><u>تغليف القرص</u>:<br />شمع الكارنوبا، أكسيد فيروسوفيريك ، الهيبرومليوز، أكسيد الحديد الأحمر &nbsp;، أكسيد الحديد الأصفر، أحادي هيدرات اللاكتوز، وثاني أوكسيد التيتانيوم،&nbsp; وتراياكتين.<br /><br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الأقراص ذات لون بيج، بيضاوية الشكل مُرَمْزَة بِـ ( 770 ) على أحد الجوانب . الأقراص بطول 21 مم و عرض 10 مم. يتم تعبئة الأقراص في علبة كرتونية تحتوي على شريطين من الورق المقوّى، كل شريط من الورق المقوّى يحتوي على اثنين من شرائط الألومنيوم ذات 7 أقراص. تحتوي كل عبوة على عدد 28 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong></p><p dir="RTL">ميرك شارب و دوم بي.في.، واردرويج 39،</p><p dir="RTL">2031 بي ان هارلم, هولندا</p><p>&nbsp;</p><p><strong>الشركة المُصَنِّعة</strong></p><p>شيرينغ بلاو لابو إن في، إندستريبارك ٠ ٣، المنطقة أ</p><p>بي- ٢٢٢٠ هايست- أوب- دن- بيرغ</p><p>&nbsp;بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ نوفمبر 2021

للإبلاغ عن الأعراض الجانبية:

•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.






( إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك و استهلاكه خلافًا للتعليمات يعرضك للخطر
- اتّبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إنّ الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال
مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
     تمت الموافقة على نشرة معلومات المريض هَذهِ من قِبَل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية



        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zepatier 50 mg/100 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zepatier film-coated tablets contains 50 mg elbasvir and 100 mg grazoprevir. 
Excipients with known effect
Each film-coated tablet contains 87.02 mg of lactose (as monohydrate) and 3.04 mmol (or 69.85 mg) of sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Beige, oval tablet of dimensions 21 mm x 10 mm debossed with “770” on one side and plain on the other.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zepatier&nbsp; is indicated for the treatment of chronic hepatitis C (CHC) in adults. (see sections 4.2, 4.4 and 5.1).</p><p>For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ZEPATIER treatment should be initiated and monitored by a physician experienced in the</p><p>management of patients with CHC.</p><p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>The recommended dose is one tablet once daily.</p><p>&nbsp;</p><p>Recommended regimens and treatment durations are provided in Table 1 below (see sections 4.4</p><p>and 5.1):</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><strong>Table 1 - Recommended Zepatier therapy for Treatment of Chronic Hepatitis C Infection in Patients with or without compensated cirrhosis (Child-Pugh A only) </strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:26.5pt; vertical-align:top; width:136.55pt"><p><strong>HCV genotype</strong></p></td><td style="border-color:black; height:26.5pt; vertical-align:top; width:327.85pt"><p><strong>Treatment and duration</strong></p></td></tr><tr><td style="border-color:black; height:104.5pt; vertical-align:top; width:136.55pt"><p>1a</p></td><td style="height:104.5pt; vertical-align:top; width:327.85pt"><p>Zepatier for 12 weeks</p><p>&nbsp;</p><p>Zepatier for 16 weeks plus ribavirinA&nbsp;should be considered in patients with baseline HCV RNA level &gt;800,000 IU/ml and/or the presence of specific NS5A polymorphisms causing at least a 5-fold reduction in activity of elbasvir to minimise the risk of treatment failure (see section 5.1).</p></td></tr><tr><td style="border-color:black; height:26.5pt; vertical-align:top; width:136.55pt"><p>1b</p></td><td style="height:26.5pt; vertical-align:top; width:327.85pt"><p>Zepatier for 12 weeks</p></td></tr><tr><td style="border-color:black; height:78.85pt; vertical-align:top; width:136.55pt"><p>4</p></td><td style="height:78.85pt; vertical-align:top; width:327.85pt"><p>Zepatier for 12 weeks</p><p>&nbsp;</p><p>Zepatier for 16 weeks plus ribavirinA&nbsp;should be considered in patients with baseline HCV RNA level &gt;800,000 IU/ml to minimise the risk of treatment failure (see section 5.1).</p></td></tr></tbody></table><p><strong><sup>A</sup></strong><strong> </strong>In the clinical studies, the dose of ribavirin was weight-based (&lt; 66 kg = 800 mg/day, 66 to 80 kg = 1,000 mg/day, 81 to 105 kg = 1,200 mg/day, &gt; 105 kg = 1,400 mg/day) administered in two divided doses with food.</p><p><strong>&nbsp;</strong></p><p>For specific dosage instructions for ribavirin, including dose modification, refer to the ribavirin Summary of Product Characteristics.</p><p>&nbsp;</p><p>Patients should be instructed that if vomiting occurs within 4 hours of dosing, an additional tablet can be taken up to 8 hours before the next dose. If vomiting occurs more than 4 hours after dosing, no further dose is needed.</p><p>&nbsp;</p><p>In case a dose of Zepatier is missed and it is within 16 hours of the time Zepatier is usually</p><p>taken, the patient should be instructed to take Zepatier as soon as possible and then take the next dose of Zepatier at the usual time. If more than 16 hours have passed since ZEPATIER is usually taken, then the patient should be instructed that the missed dose should NOT be taken and to take the next dose per the usual dosing schedule. Patients should be instructed not to take a double dose.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment of Zepatier is required for elderly patients (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Renal Impairment and end stage renal disease (ESRD)</em></p><p>No dose adjustment of Zepatier is required in patients with mild, moderate, or severe renal</p><p>impairment (including patients receiving haemodialysis or peritoneal dialysis) (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Hepatic Impairment</em></p><p>No dose adjustment of Zepatier is required in patients with mild hepatic impairment (Child-Pugh A). Zepatier is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) (see sections 4.3 and 5.2).</p><p>&nbsp;</p><p>The safety and efficacy of Zepatier have not been established in liver transplant recipients.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Zepatier in children and adolescents aged less than 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p><p>The film-coated tablets should be swallowed whole and may be taken with or without food (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Patients with moderate or severe hepatic impairment (Child-Pugh B or C) (see sections 4.2 and 5.2). 

Co-administration with inhibitors of  organic anion transporting polypeptide 1B (OATP1B), such as rifampicin, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cobicistat or ciclosporin (see sections 4.4 and 4.5).

Co-administration with inducers of cytochrome P450 3A (CYP3A), or P-glycoprotein (P-gp), such as efavirenz, phenytoin, carbamazepine, bosentan, etravirine, modafinil or St. John’s wort (Hypericum perforatum) (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>ALT elevations</u></p><p>&nbsp;</p><p>The rate of late ALT elevations during treatment is directly related to the plasma exposure to grazoprevir. During clinical studies with ZEPATIER with or without ribavirin, &lt; 1 % of subjects experienced elevations of ALT from normal levels to greater than 5 times the upper limit of normal</p><p>(ULN), (see section 4.8). Higher rates of late ALT elevations occurred in females (2 % [11/652]), Asians (2 % [4/165]), and subjects aged &ge; 65 years (2 % [3/187]) (see sections 4.8 and 5.2). These late ALT elevations generally occurred at or after treatment week 8.</p><p>&nbsp;</p><p>Hepatic laboratory testing should be performed prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, additional hepatic laboratory testing should be performed at treatment week 12.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients should be instructed to consult their healthcare professional without delay if they have</p><p>onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinuation of ZEPATIER should be considered if ALT levels are confirmed to be greater</p><p>than 10 times the ULN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ZEPATIER should be discontinued if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or international normalised ratio (INR).</p><p>&nbsp;</p><p><u>Genotype-specific activity</u></p><p>&nbsp;</p><p>The efficacy of ZEPATIER has not been demonstrated in HCV genotypes 2, 3, 5 and 6. ZEPATIER is not recommended in patients infected with these genotypes.</p><p>&nbsp;</p><p><u>Retreatment</u></p><p>&nbsp;</p><p>The efficacy of ZEPATIER in patients previously exposed to ZEPATIER, or to medicinal products of the same classes as those of ZEPATIER (NS5A inhibitors or NS3/4A inhibitors other than telaprevir, simeprevir, boceprevir), has not been demonstrated (see section 5.1).</p><p>&nbsp;</p><p><u>Interactions with medicinal products</u></p><p>&nbsp;</p><p>Co-administration of ZEPATIER and OATP1B inhibitors is contraindicated because it may significantly increase grazoprevir plasma concentrations.</p><p>&nbsp;</p><p>Co-administration of ZEPATIER and CYP3A or P-gp inducers is contraindicated because it may significantly decrease elbasvir and grazoprevir plasma concentrations and may lead to a reduced therapeutic effect of ZEPATIER (see sections 4.3, 4.5 and 5.2).</p><p>&nbsp;</p><p>The concomitant use of ZEPATIER and strong CYP3A inhibitors increases elbasvir and grazoprevir concentrations, and co-administration is not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>HCV/HBV (hepatitis B virus) co-infection</u></p><p>&nbsp;</p><p>Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents. HBV screening should be performed in all patients before initiation of treatment. HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current clinical guidelines.</p><p>&nbsp;</p><p><u>Use in diabetic patients</u></p><p>&nbsp;</p><p>Diabetics may experience improved glucose control potentially resulting in symptomatic hypoglycaemia, after initiating HCV direct acting antiviral (DAA) treatment. Glucose levels of diabetic patients initiating DAA therapy should be closely monitored, particularly within the first 3 months, and their diabetic medication modified when necessary. The physician in charge of the diabetic care of the patient should be informed when DAA therapy is initiated.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>ZEPATIER is not indicated for use in children under 12 years of age. <u>Excipients</u></p><p>ZEPATIER contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>ZEPATIER contains 69.85 mg sodium per tablet, equivalent to 3.5 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicinal products to affect ZEPATIER</u></p><p>&nbsp;</p><p>Grazoprevir is a substrate of OATP1B drug transporters. Co-administration of ZEPATIER with medicinal products &nbsp;that inhibit OATP1B transporters is contraindicated because it may result in a significant increase in the plasma concentration of grazoprevir (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Elbasvir and grazoprevir are substrates of CYP3A and P-gp. Co-administration of inducers of CYP3A or P-gp with ZEPATIER is contraindicated because it may decrease elbasvir and grazoprevir plasma concentrations, which may lead to reduced therapeutic effect of ZEPATIER (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Co-administration of ZEPATIER with strong CYP3A inhibitors increases elbasvir and grazoprevir plasma concentrations , and co-administration is not recommended (see Table 2 and section 4.4).</p><p>&nbsp;</p><p>Co-administration of ZEPATIER with P-gp inhibitors is expected to have a minimal effect on the plasma concentrations of ZEPATIER.</p><p>&nbsp;</p><p>The potential for grazoprevir to be a breast cancer resistance protein (BCRP) substrate cannot be</p><p>excluded.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Potential for ZEPATIER to affect other medicinal products</u></p><p>&nbsp;</p><p>Elbasvir and grazoprevir are inhibitors of the drug transporter BCRP at the intestinal level in humans and may increase plasma concentrations of co-administered BCRP substrates. Elbasvir is not a CYP3A inhibitor in vitro and grazoprevir is a weak CYP3A inhibitor in humans. Co-administration with grazoprevir did not result in clinically relevant increases in exposures of CYP3A substrates.</p><p>&nbsp;</p><p>Therefore, no dose adjustment is required for CYP3A substrates when co-administered with</p><p>ZEPATIER.</p><p>&nbsp;</p><p>Elbasvir has minimal intestinal P-gp inhibition in humans, and does not result in clinically relevant</p><p>increases in concentrations of digoxin (a P-gp substrate), with an 11% increase in plasma AUC.</p><p>Grazoprevir is not a P-gp inhibitor based on in vitro data. Elbasvir and grazoprevir are not OATP1B inhibitors in humans. Based on in vitro data, clinically significant interactions with ZEPATIER as an inhibitor of other CYP enzymes, UGT1A1, esterases (CES1, CES2, and CatA), OAT1, OAT3, and OCT2 are not expected. Based on in vitro data, a potential for GZR to inhibit BSEP cannot be excluded. Multiple-dose administration of elbasvir or grazoprevir is unlikely to induce the metabolism of medicinal products metabolised by CYP isoforms based on in vitro data.</p><p>&nbsp;</p><p><u>Patients treated with vitamin K antagonists</u></p><p>As liver function may change during treatment with ZEPATIER, a close monitoring of International Normalised Ratio (INR) values is recommended.</p><p>&nbsp;</p><p><u>Impact of</u> <u>DAA therapy on drugs metabolized by the liver</u></p><p>&nbsp;</p><p>Grazoprevir&rsquo;s weak inhibition of CYP3A may increase levels of CYP3A substrates. In addition, the plasma concentrations of drugs that are CYP3A substrates may be decreased by improvement in liver function during DAA therapy, related to clearance of HCV. Therefore, close monitoring and potential dose adjustment of CYP3A substrates with a narrow therapeutic index (e.g., calcineurin inhibitors) may be required during therapy, as drug levels may change (see Table 2).</p><p>&nbsp;</p><p><u>Interactions between ZEPATIER and other medicinal products &nbsp;</u></p><p>Table 2 provides a listing of assessed or potential medicinal product interactions. An up &ldquo;&uarr;&rdquo; or down &ldquo;&darr;&rdquo; arrow represents a change in exposure that requires monitoring or a dose adjustment of that medication, or the co-administration is not recommended or contraindicated. No clinically relevant change in exposure is represented by a horizontal arrow &ldquo;&harr;&rdquo;.</p><p>&nbsp;</p><p>The medicinal product interactions described are based on results from studies conducted with either ZEPATIER or elbasvir (EBR) and grazoprevir (GZR) as individual agents, or are predicted medicinal product interactions that may occur with elbasvir or grazoprevir. The table is not all-inclusive.</p><p>&nbsp;</p><p><strong>Table 2: Interactions and dose recommendations with other medicinal products </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with Zepatier</strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p><strong><em>ACID REDUCING AGENTS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p><em>H2-receptor antagonists</em></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Famotidine</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="9" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(20 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.05 (0.92, 1.18)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir (50</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.11 (0.98, 1.26)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>mg single dose)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.03 (0.91, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir (100</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>mg single dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.10 (0.95, 1.28)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C<sub>max</sub> 0.89 (0.71, 1.11)</p></td></tr><tr><td style="height:12.7pt; vertical-align:top; width:193.1pt"><p>C24 1.12 (0.97, 1.30)</p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p><em>Proton pump inhibitors</em></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Pantoprazole</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="9" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(40 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.05 (0.93, 1.18)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.02 (0.92, 1.14)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>single dose)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.03 (0.92, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir (100</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>mg single dose)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.12 (0.96, 1.30)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.10 (0.89, 1.37)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.17 (1.02, 1.34)</p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p><em>Antacids</em></p></td></tr><tr><td style="border-color:black; height:46.45pt; vertical-align:top; width:91.3pt"><p>Aluminium or magnesium hydroxide; calcium carbonate</p></td><td style="height:46.45pt; vertical-align:top; width:193.1pt"><p>Interaction not studied. Expected:</p><p>&harr; Elbasvir</p><p>&harr; Grazoprevir</p></td><td style="height:46.45pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ANTIARRHYTHMICS</em></strong></p></td></tr><tr><td style="border-color:black; height:57.95pt; vertical-align:top; width:91.3pt"><p>Digoxin</p><p>(0.25 mg single dose)/ elbasvir</p><p>(50 mg once daily)</p></td><td style="height:57.95pt; vertical-align:top; width:193.1pt"><p>&harr; Digoxin</p><p>AUC 1.11 (1.02, 1.22)</p><p>Cmax 1.47 (1.25, 1.73)</p><p>&nbsp;</p><p>(P-gp inhibition)</p></td><td style="height:57.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>ANTICOAGULANTS</em></strong></p></td></tr><tr><td style="border-color:black; height:65.5pt; vertical-align:top; width:91.3pt"><p>Dabigatran etexilate</p></td><td style="height:65.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied. Expected:</p><p>&uarr; Dabigatran</p><p>&nbsp;</p><p>(P-gp inhibition)</p></td><td style="height:65.5pt; vertical-align:top; width:181.7pt"><p>Concentrations of dabigatran may increase when co-administered with elbasvir, with possible increased bleeding risk. Clinical and laboratory monitoring is recommended.</p></td></tr><tr><td style="border-color:black; height:52.55pt; vertical-align:top; width:91.3pt"><p>Vitamin K antagonists</p></td><td style="height:52.55pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p></td><td style="height:52.55pt; vertical-align:top; width:181.7pt"><p>Close monitoring of INR is recommended with all vitamin K antagonists. This is due to liver function changes during treatment with Zepatier.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>ANTICONVULSANTS</em></strong></p></td></tr><tr><td style="border-color:black; height:69.5pt; vertical-align:top; width:91.3pt"><p>Carbamazepine Phenytoin</p></td><td style="height:69.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied. Expected:</p><p>&darr; Elbasvir</p><p>&darr; Grazoprevir</p><p>&nbsp;</p><p>(CYP3A or P-gp induction)</p></td><td style="height:69.5pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ANTIFUNGALS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:16.2pt; vertical-align:top; width:466.1pt"><p>Ketoconazole</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(400 mg PO once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="5" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>Co-administration is not recommended.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.80 (1.41, 2.29)</p></td></tr><tr><td rowspan="2" style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg single dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.29 (1.00, 1.66)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.89 (1.37, 2.60)</p></td></tr><tr><td style="border-color:black; height:64.1pt; vertical-align:top; width:91.3pt"><p>(400 mg PO once daily)/ grazoprevir (100 mg single dose)</p></td><td style="height:64.1pt; vertical-align:top; width:193.1pt"><p><strong>&uarr; </strong>Grazoprevir</p><p>AUC 3.02 (2.42, 3.76)</p><p>Cmax 1.13 (0.77, 1.67)</p><p>&nbsp;</p><p>(CYP3A inhibition)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ANTIMYCOBACTERIALS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:11.9pt; vertical-align:top; width:466.1pt"><p>Rifampicin</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:91.3pt"><p>(600 mg IV single</p></td><td style="height:12.05pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="13" style="height:12.05pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.22 (1.06, 1.40)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg single dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.41 (1.18, 1.68)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.31 (1.12, 1.53)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg IV single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 10.21 (8.68, 12.00)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 10.94 (8.92, 13.43)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>dose)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 1.77 (1.40, 2.24)</p></td></tr><tr><td style="height:17.25pt; vertical-align:top; width:193.1pt"><p>(OATP1B inhibition)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg PO single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.17 (0.98, 1.39)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg single dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.29 (1.06, 1.58)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.21 (1.03, 1.43)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg PO single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td><td rowspan="10" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 8.35 (7.38, 9.45)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 6.52 (5.16, 8.24)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 1.31 (1.12, 1.53)</p></td></tr><tr><td style="height:17.25pt; vertical-align:top; width:193.1pt"><p>(OATP1B inhibition)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg PO once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.93 (0.75, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.16 (0.82, 1.65)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.10 (0.07, 0.13)</p></td></tr><tr><td style="height:17.25pt; vertical-align:top; width:193.1pt"><p>(OATP1B inhibition and CYP3A induction)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ASTHMA AGENTS</em></strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Montelukast</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Montelukast</p></td><td rowspan="5" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(10 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.11 (1.01, 1.20)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.92 (0.81, 1.06)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg single</p></td><td rowspan="2" style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.39 (1.25, 1.56)</p></td></tr><tr><td style="border-color:black; height:11.55pt; vertical-align:top; width:91.3pt"><p>dose)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ENDOTHELIN ANTAGONIST</em></strong></p></td></tr><tr><td style="border-color:black; height:69.5pt; vertical-align:top; width:91.3pt"><p>Bosentan</p></td><td style="height:69.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied. Expected:</p><p>&darr; Elbasvir</p><p>&darr; Grazoprevir</p><p>&nbsp;</p><p>(CYP3A or P-gp induction)</p></td><td style="height:69.5pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>HCV ANTIVIRAL AGENTS</em></strong></p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:91.3pt"><p>Sofosbuvir</p></td><td style="height:12.05pt; vertical-align:top; width:193.1pt"><p>&harr; Sofosbuvir</p></td><td rowspan="8" style="height:12.05pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(400 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 2.43 (2.12, 2.79)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose sofosbuvir)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 2.27 (1.72, 2.99)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; GS-331007</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.13 (1.05, 1.21)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once daily</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.87 (0.78, 0.96)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.53 (1.43, 1.63)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>HERBAL SUPPLEMENTS</em></strong></p></td></tr><tr><td style="border-color:black; height:69.5pt; vertical-align:top; width:91.3pt"><p>St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</p></td><td style="height:69.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Elbasvir</p><p>&darr; Grazoprevir</p><p>&nbsp;</p><p>(CYP3A or P-gp induction)</p></td><td style="height:69.5pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3" style="border-color:black; height:25.8pt; vertical-align:top; width:466.1pt"><p><strong><em>HBV AND HIV ANTIVIRAL AGENTS: NUCLEOS(T)IDE REVERSE TRANSCRIPTASE</em></strong><strong><em> </em></strong><strong><em>INHIBITORS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Tenofovir disoproxil fumarate</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="8" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.93 (0.82, 1.05)</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.88 (0.77, 1.00)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.92 (0.18, 1.05)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Tenofovir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.34 (1.23, 1.47)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.47 (1.32, 1.63)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.29 (1.18, 1.41)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td><td rowspan="14" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.86 (0.55, 1.12)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.78 (0.51, 1.18)</p></td></tr><tr><td rowspan="5" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.89 (0.78, 1.01)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Tenofovir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.18 (1.09, 1.28)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.14 (1.04, 1.25)</p></td></tr><tr><td style="height:14.9pt; vertical-align:top; width:193.1pt"><p>C24 1.24 (1.10, 1.39)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Tenofovir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.27 (1.20, 1.35)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.14 (0.95, 1.36)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/grazoprevir</p></td><td rowspan="3" style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.23 (1.09, 1.40)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg once</p></td></tr><tr><td style="border-color:black; height:16.35pt; vertical-align:top; width:91.3pt"><p>daily)</p></td></tr><tr><td style="border-color:black; height:93.05pt; vertical-align:top; width:91.3pt"><p>Lamivudine Abacavir Entecavir</p></td><td style="height:93.05pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Elbasvir</p><p>&harr; Grazoprevir</p><p>&harr; Lamivudine</p><p>&harr; Abacavir</p><p>&harr; Entecavir</p><p><!--[if !supportLists]-->&mdash;&nbsp; <!--[endif]-->Entecavir</p></td><td rowspan="8" style="height:93.05pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:12.7pt; vertical-align:top; width:91.3pt"><p>Emtricitabine</p></td><td style="height:12.7pt; vertical-align:top; width:193.1pt"><p>Interaction studied with</p></td></tr><tr><td rowspan="6" style="border-color:black; height:27.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p><p>daily)</p></td><td style="height:27.5pt; vertical-align:top; width:193.1pt"><p>elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (fixed-dose</p></td></tr><tr><td style="height:.25in; vertical-align:top; width:193.1pt"><p>combination)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Emtricitabine</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.07 (1.03, 1.10)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.96 (0.90, 1.02)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.19 (1.13, 1.25)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>HIV ANTIVIRAL AGENTS: PROTEASE INHIBITORS</em></strong></p></td></tr><tr><td colspan="2" style="border-color:black; height:12.0pt; vertical-align:top; width:3.95in"><p>Atazanavir/ritonavir</p></td><td rowspan="23" style="height:12.0pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Elbasvir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 4.76 (4.07, 5.56)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(100 mg once daily/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 4.15 (3.46, 4.97)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 6.45 (5.51, 7.54)</p></td></tr><tr><td rowspan="7" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>once daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>(combination of mechanisms including</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>CYP3A inhibition)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&mdash; Atazanavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.07 (0.98, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.02 (0.96, 1.08)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.15 (1.02, 1.29)</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:12.05pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 10.58 (7.78, 14.39)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(100 mg once daily/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 6.24 (4.42, 8.81)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 11.64 (7.96, 17.02)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>(combination of OATP1B and CYP3A</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>inhibition)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Atazanavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.43 (1.30, 1.57)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.12 (1.01, 1.24)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.23 (1.13, 2.34)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td colspan="2" style="border-color:black; height:12.0pt; vertical-align:top; width:3.95in"><p>Darunavir/ritonavir</p></td><td rowspan="45" style="height:12.0pt; vertical-align:top; width:181.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg twice</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.66 (1.35, 2.05)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(100 mg twice</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.67 (1.36, 2.05)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily/ elbasvir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.82 (1.39, 2.39)</p></td></tr><tr><td rowspan="5" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Darunavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.95 (0.86, 1.06)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.95 (0.85, 1.05)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 0.94 (0.85, 1.05)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg twice</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 7.50 (5.92, 9.51)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg twice</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 5.27 (4.04, 6.86)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 8.05 (6.33, 10.24)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>(combination of OATP1B and CYP3A</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>inhibition)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Darunavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.11 (0.99, 1.24)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.10 (0.96, 1.25)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 1.00 (0.85, 1.18)</p></td></tr><tr><td colspan="2" style="border-color:black; height:12.0pt; vertical-align:top; width:3.95in"><p>Lopinavir/ritonavir</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(400 mg twice</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Elbasvir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 3.71 (3.05, 4.53)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg twice</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 2.87 (2.29, 3.58)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 4.58 (3.72, 5.64)</p></td></tr><tr><td rowspan="7" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>(combination of mechanisms including</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>CYP3A inhibition)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Lopinavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.02 (0.93, 1.13)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.02 (0.92, 1.13)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 1.07 (0.97, 1.18)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(400 mg twice</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/ ritonavir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 12.86 (10.25, 16.13)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg twice</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 7.31 (5.65, 9.45)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 21.70 (12.99, 36.25)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>(combination of OATP1B and CYP3A</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>inhibition)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Lopinavir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.03 (0.96, 1.16)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.97 (0.88, 1.08)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 0.97 (0.81, 1.15)</p></td></tr><tr><td style="border-color:black; height:69.5pt; vertical-align:top; width:91.3pt"><p>Saquinavir/ritonavir Tipranavir/ritonavir Atazanavir</p></td><td style="height:69.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&uarr; Grazoprevir</p><p>&nbsp;</p><p>(combination of mechanisms including CYP3A inhibition)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:25.8pt; vertical-align:top; width:466.1pt"><p><strong><em>HIV </em></strong><strong><em>ANTIVIRAL</em></strong><strong><em> AGENTS: NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE</em></strong><strong><em> </em></strong><strong><em>INHIBITORS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Efavirenz</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&darr; Elbasvir</p></td><td rowspan="18" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.46 (0.36, 0.59)</p></td></tr><tr><td rowspan="7" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.55 (0.41, 0.73)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.41 (0.28, 0.59)</p></td></tr><tr><td style="height:23.0pt; vertical-align:top; width:193.1pt"><p>(CYP3A or P-gp induction)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Efavirenz</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.82 (0.78, 0.86)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.74 (0.67, 0.82)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 0.91 (0.87, 0.96)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(600 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&darr;Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.17 (0.13, 0.24)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.13 (0.09, 0.19)</p></td></tr><tr><td rowspan="6" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.31 (0.25, 0.38)</p></td></tr><tr><td style="height:23.0pt; vertical-align:top; width:193.1pt"><p>(CYP3A or P-gp induction)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Efavirenz</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.00 (0.96, 1.05)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.03 (0.99, 1.08)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 0.93 (0.88, 0.98)</p></td></tr><tr><td style="border-color:black; height:69.6pt; vertical-align:top; width:91.3pt"><p>Etravirine</p></td><td style="height:69.6pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Elbasvir</p><p>&darr; Grazoprevir</p><p>&nbsp;</p><p>(CYP3A or P-gp induction)</p></td><td style="height:69.6pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Rilpivirine</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="13" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(25 mg once daily)/</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.07 (1.00, 1.15)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.99, 1.16)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.04 (0.98, 1.11)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td rowspan="7" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 0.98 (0.89, 1.07)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.97 (0.83, 1.14)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 1.00 (0.93, 1.07)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Rilpivirine</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.13 (1.07, 1.20)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.97, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.16 (1.09, 1.23)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>HIV ANTIVIRAL AGENTS: INTEGRASE STRAND TRANSFER INHIBITORS</em></strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Dolutegravir</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="13" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 0.98 (0.93, 1.04)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.97 (0.89, 1.05)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 0.98 (0.93, 1.03)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td rowspan="7" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 0.81 (0.67, 0.97)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.64 (0.44, 0.93)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 0.86 (0.79, 0.93)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Dolutegravir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.16 (1.00, 1.34)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.22 (1.05, 1.40)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.14 (0.95, 1.36)</p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Raltegravir</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(400 mg single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="16" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.81 (0.57, 1.17)</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg single dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.89 (0.61, 1.29)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 0.80 (0.55, 1.16)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Raltegravir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.02 (0.81, 1.27)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.09 (0.83, 1.44)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 0.99 (0.80, 1.22)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(400 mg twice</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.89 (0.72, 1.09)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.85 (0.62, 1.16)</p></td></tr><tr><td rowspan="5" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.90 (0.82, 0.99)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Raltegravir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.43 (0.89, 2.30)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.46 (0.78, 2.73)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 1.47 (1.08, 2.00)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>HIV</em></strong><strong><em> </em></strong><strong><em>ANTIVIRAL</em></strong><strong><em> AGENTS: OTHER</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (fixed-dose combination)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>elvitegravir</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Elbasvir</p></td><td style="height:11.95pt; vertical-align:top; width:181.7pt"><p>Co-administration with ZEPATIER is</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(150 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 2.18 (2.02, 2.35)</p></td><td rowspan="28" style="height:11.45pt; vertical-align:top; width:181.7pt"><p>contraindicated.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/cobicistat</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.91 (1.77, 2.05)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(150 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 2.38 (2.19, 2.60)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>emtricitabine</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>(CYP3A and OATP1B inhibition)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)/ tenofovir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>disoproxil fumarate</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 5.36 (4.48, 6.43)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(300 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 4.59 (3.70, 5.69)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 2.78 (2.48, 3.11)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>(CYP3A and OATP1B inhibition)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="15" style="border-color:black; height:15.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:15.5pt; vertical-align:top; width:193.1pt"><p>&harr; Elvitegravir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.10 (1.00, 1.21)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.02 (0.93, 1.11)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 1.31 (1.11, 1.55)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Cobicistat</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.49 (1.42, 1.57)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>Cmax 1.39 (1.29, 1.50)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Emtricitabine</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.07 (1.03, 1.10)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.96 (0.90, 1.02)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 1.19 (1.13, 1.25)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Tenofovir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.18 (1.13, 1.24)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.25 (1.14, 1.37)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.20 (1.15, 1.26)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>HMG-CoA REDUCTASE INHIBITORS</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Atorvastatin</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(20 mg single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Atorvastatin</p></td><td style="height:11.95pt; vertical-align:top; width:181.7pt"><p>The dose of atorvastatin should not</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 3.00 (2.42, 3.72)</p></td><td style="height:11.45pt; vertical-align:top; width:181.7pt"><p>exceed a daily dose of 20 mg when</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 5.66 (3.39, 9.45)</p></td><td rowspan="13" style="height:11.45pt; vertical-align:top; width:181.7pt"><p>co-administered with ZEPATIER.</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>(primarily due to intestinal BCRP inhibition)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.26 (0.97, 1.64)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.26 (0.83, 1.90)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.11 (1.00, 1.23)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(10 mg single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Atorvastatin</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.94 (1.63, 2.33)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 4.34 (3.10, 6.07)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>/ grazoprevir</p></td><td rowspan="3" style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 0.21 (0.17, 0.26)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td></tr><tr><td style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Rosuvastatin</p></td></tr><tr><td style="border-color:black; height:126.95pt; vertical-align:top; width:91.3pt"><p>(10 mg single dose)/ grazoprevir (200 mg once daily)</p></td><td style="height:126.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Rosuvastatin</p><p>AUC 1.59 (1.33, 1.89)</p><p>Cmax 4.25 (3.25, 5.56)</p><p>C24 0.80 (0.70, 0.91)</p><p>&nbsp;</p><p>(intestinal BCRP inhibition)</p><p>&nbsp;</p><p>&harr; Grazoprevir</p><p>AUC 1.16 (0.94, 1.44)</p><p>Cmax 1.13 (0.77, 1.65)</p><p>C24 0.93 (0.84, 1.03)</p></td><td rowspan="15" style="height:126.95pt; vertical-align:top; width:181.7pt"><p>The dose of rosuvastatin should not exceed a daily dose of 10 mg when co-administered with ZEPATIER.</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(10 mg single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&uarr; Rosuvastatin</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 2.26 (1.89, 2.69)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 5.49 (4.29, 7.04)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 0.98 (0.84, 1.13)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="9" style="border-color:black; height:17.2pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>(intestinal BCRP inhibition)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.09 (0.98, 1.21)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.11 (0.99, 1.26)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.96 (0.86, 1.08)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.01 (0.79, 1.28)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.97 (0.63, 1.50)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 0.95 (0.87, 1.04)</p></td></tr><tr><td style="border-color:black; height:126.95pt; vertical-align:top; width:91.3pt"><p>Fluvastatin Lovastatin Simvastatin</p></td><td style="height:126.95pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&uarr; Fluvastatin</p><p>(primarily due to intestinal BCRP inhibition)</p><p>&nbsp;</p><p>&uarr; Lovastatin (CYP3A inhibition)</p><p>&nbsp;</p><p>&uarr; Simvastatin</p><p>(primarily due to intestinal BCRP inhibition and CYP3A inhibition)</p></td><td style="height:126.95pt; vertical-align:top; width:181.7pt"><p>The dose of fluvastatin, lovastatin, or simvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER.</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Pitavastatin</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Pitavastatin</p></td><td rowspan="8" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(1 mg single dose)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.11 (0.91, 1.34)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.27 (1.07, 1.52)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.81 (0.70, 0.95)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.72 (0.57, 0.92)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 0.91 (0.82, 1.01)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Pravastatin</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Pravastatin</p></td><td rowspan="12" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(40 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.33 (1.09, 1.64)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.28 (1.05, 1.55)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.98 (0.93, 1.02)</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.97 (0.89, 1.05)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 0.97 (0.92, 1.02)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.24 (1.00, 1.53)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.42 (1.00, 2.03)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 1.07 (0.99, 1.16)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>IMMUNOSUPPRESSANTS</em></strong></p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:91.3pt"><p>Ciclosporin</p></td><td style="height:12.05pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="15" style="height:12.05pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(400 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.98 (1.84, 2.13)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.95 (1.84, 2.07)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 2.21 (1.98, 2.47)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&uarr; Grazoprevir</p></td></tr><tr><td rowspan="9" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 15.21 (12.83, 18.04)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 17.00 (12.94, 22.34)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 3.39 (2.82, 4.09)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>(due in part to OATP1B and CYP3A</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>inhibition)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Ciclosporin</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.96 (0.90, 1.02)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.90 (0.85, 0.97)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C12 1.00 (0.92, 1.08)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Mycophenolate</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="12" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>mofetil</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.07 (1.00, 1.14)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(1,000 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.98, 1.16)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.05 (0.97, 1.14)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.74 (0.60, 0.92)</p></td></tr><tr><td rowspan="5" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 0.58 (0.42, 0.82)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.97 (0.89, 1.06)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Mycophenolic acid</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.95 (0.87, 1.03)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>Cmax 0.85 (0.67, 1.07)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="border-color:black; height:224.9pt; vertical-align:top; width:91.3pt"><p>Prednisone (40 mg single</p><p>dose)/ elbasvir</p><p>(50 mg once daily)/ grazoprevir</p><p>(200 mg once daily</p></td><td style="height:224.9pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p><p>AUC 1.17 (1.11, 1.24)</p><p>Cmax 1.25 (1.16, 1.35)</p><p>C24 1.04 (0.97, 1.12)</p><p>&nbsp;</p><p>&harr; Grazoprevir</p><p>AUC 1.09 (0.95, 1.25)</p><p>Cmax 1.34 (1.10, 1.62)</p><p>C24 0.93 (0.87, 1.00)</p><p>&nbsp;</p><p>&harr; Prednisone</p><p>AUC 1.08 (1.00, 1.17)</p><p>Cmax 1.05 (1.00, 1.10)</p><p>&nbsp;</p><p>&harr; Prednisolone</p><p>AUC 1.08 (1.01, 1.16)</p><p>Cmax 1.04 (0.99, 1.09)</p></td><td style="height:224.9pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Tacrolimus</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td style="height:11.95pt; vertical-align:top; width:181.7pt"><p>Frequent monitoring of tacrolimus whole</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(2 mg single dose)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.97 (0.90, 1.06)</p></td><td style="height:11.5pt; vertical-align:top; width:181.7pt"><p>blood concentrations, changes in renal</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.99 (0.88, 1.10)</p></td><td style="height:11.5pt; vertical-align:top; width:181.7pt"><p>function, and tacrolimus-associated</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>once daily)/</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 0.92 (0.83, 1.02)</p></td><td style="height:11.45pt; vertical-align:top; width:181.7pt"><p>adverse events upon the initiation of co-</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td><td rowspan="10" style="height:11.5pt; vertical-align:top; width:181.7pt"><p>administration is recommended.</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td rowspan="8" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.12 (0.97, 1.30)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.83, 1.37)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>C24 0.94 (0.87, 1.02)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&uarr; Tacrolimus</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.43 (1.24, 1.64)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.60 (0.52, 0.69)</p></td></tr><tr><td style="height:17.35pt; vertical-align:top; width:193.1pt"><p>C12 1.70 (1.49, 1.94)</p></td></tr><tr><td style="height:18.35pt; vertical-align:top; width:193.1pt"><p>(CYP3A inhibition)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>KINASE INHIBITOR</em></strong></p></td></tr><tr><td style="border-color:black; height:69.35pt; vertical-align:top; width:91.3pt"><p>Sunitinib</p></td><td style="height:69.35pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&uarr; sunitinib</p><p>&nbsp;</p><p>(possibly due to intestinal BCRP inhibition)</p></td><td style="height:69.35pt; vertical-align:top; width:181.7pt"><p>Co-administration of ZEPATIER with sunitinib may increase sunitinib concentrations leading to an increased risk of sunitinib-associated adverse events.</p><p>Use with caution; dose adjustment of sunitinib may be required.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>OPIOID-SUBSTITUTION THERAPY</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Buprenorphine/naloxone</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(8 mg/2 mg single</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="11" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.22 (0.98, 1.52)</p></td></tr><tr><td rowspan="9" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg single dose)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.13 (0.87, 1.46)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 1.22 (0.99, 1.51)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; Buprenorphine</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.98 (0.89, 1.08)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.94 (0.82, 1.08)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 0.98 (0.88, 1.09)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>&harr; Naloxone</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.88 (0.76, 1.02)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>Cmax 0.85 (0.66, 1.09)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(8-24 mg/2-6 mg</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td><td rowspan="8" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>once daily)/</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.80 (0.53, 1.22)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.76 (0.40, 1.44)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 0.69 (0.54, 0.88)</p></td></tr><tr><td rowspan="4" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Buprenorphine</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.98 (0.81, 1.19)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>Cmax 0.90 (0.76, 1.07)</p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Methadone</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(20-120 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; R-Methadone</p></td><td rowspan="15" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.03 (0.92, 1.15)</p></td></tr><tr><td rowspan="6" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg once daily)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.95, 1.20)</p></td></tr><tr><td style="height:17.2pt; vertical-align:top; width:193.1pt"><p>C24 1.10 (0.96, 1.26)</p></td></tr><tr><td style="height:17.3pt; vertical-align:top; width:193.1pt"><p>&harr; S-Methadone</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.09 (0.94, 1.26)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.09 (0.95, 1.25)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 1.20 (0.98, 1.47)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(20-150 mg once</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; R-Methadone</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.09 (1.02, 1.17)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.03 (0.96, 1.11)</p></td></tr><tr><td rowspan="4" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; S-Methadone</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 1.23 (1.12, 1.35)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.15 (1.07, 1.25)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>ORAL CONTRACEPTIVES</em></strong></p></td></tr><tr><td colspan="3" style="border-color:black; height:12.0pt; vertical-align:top; width:466.1pt"><p>Ethinyl oestradiol (EE) / Levonorgestrel (LNG)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(0.03 mg EE/</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; EE</p></td><td rowspan="14" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>0.15 mg LNG</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.01 (0.97, 1.05)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>single-dose)/</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.10 (1.05, 1.16)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>elbasvir (50 mg</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>once daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; LNG</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.14 (1.04, 1.24)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>Cmax 1.02 (0.95, 1.08)</p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>(0.03 mg EE/</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; EE</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>0.15 mg LNG</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.10 (1.05, 1.14)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>single-dose)/</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>Cmax 1.05 (0.98, 1.12)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>grazoprevir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(200 mg once</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; LNG</p></td></tr><tr><td rowspan="2" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>daily)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.23 (1.15, 1.32)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>Cmax 0.93 (0.84, 1.03)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>PHOSPHATE BINDERS</em></strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Calcium acetate</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="9" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(2,668 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.92 (0.75, 1.14)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.86 (0.71, 1.04)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(50 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>C24 0.87 (0.70, 1.09)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(100 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td rowspan="3" style="border-color:black; height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>AUC 0.79 (0.68, 0.91)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.57 (0.40, 0.83)</p></td></tr><tr><td style="height:11.55pt; vertical-align:top; width:193.1pt"><p>C24 0.77 (0.61, 0.99)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:46.55pt; vertical-align:top; width:91.3pt"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:193.1pt"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90 % confidence interval) for AUC, C</strong><strong>max,</strong><strong> </strong><strong>C</strong><strong>12 </strong><strong>or C</strong><strong>24</strong></p><p><strong>(likely mechanism of interaction)</strong></p></td><td style="border-color:black; height:46.55pt; vertical-align:top; width:181.7pt"><p><strong>Recommendation concerning co- administration with ZEPATIER</strong></p></td></tr><tr><td style="height:11.95pt; vertical-align:top; width:91.3pt"><p>Sevelamer</p></td><td style="height:11.95pt; vertical-align:top; width:193.1pt"><p>&harr; Elbasvir</p></td><td rowspan="9" style="height:11.95pt; vertical-align:top; width:181.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>carbonate</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 1.13 (0.94, 1.37)</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(2,400 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 1.07 (0.88, 1.29)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>dose)/ elbasvir</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>C24 1.22 (1.02, 1.45)</p></td></tr><tr><td style="height:11.45pt; vertical-align:top; width:91.3pt"><p>(50 mg single</p></td><td style="height:11.45pt; vertical-align:top; width:193.1pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)/ grazoprevir</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>&harr; Grazoprevir</p></td></tr><tr><td style="height:11.5pt; vertical-align:top; width:91.3pt"><p>(100 mg single</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>AUC 0.82 (0.68, 0.99)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:11.5pt; vertical-align:top; width:91.3pt"><p>dose)</p></td><td style="height:11.5pt; vertical-align:top; width:193.1pt"><p>Cmax 0.53 (0.37, 0.76)</p></td></tr><tr><td style="height:14.55pt; vertical-align:top; width:193.1pt"><p>C24 0.84 (0.71, 0.99)</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.1pt; vertical-align:top; width:466.1pt"><p><strong><em>SEDATIVES</em></strong></p></td></tr><tr><td style="border-color:black; height:57.95pt; vertical-align:top; width:91.3pt"><p>Midazolam</p><p>(2 mg single dose)/ grazoprevir</p><p>(200 mg once daily)</p></td><td style="height:57.95pt; vertical-align:top; width:193.1pt"><p>&harr; Midazolam</p><p>AUC 1.34 (1.29, 1.39)</p><p>Cmax 1.15 (1.01, 1.31)</p></td><td style="height:57.95pt; vertical-align:top; width:181.7pt"><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3" style="border-color:black; height:13.2pt; vertical-align:top; width:466.1pt"><p><strong><em>STIMULANTS</em></strong></p></td></tr><tr><td style="border-color:black; height:69.5pt; vertical-align:top; width:91.3pt"><p>Modafinil</p></td><td style="height:69.5pt; vertical-align:top; width:193.1pt"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Elbasvir</p><p>&darr; Grazoprevir</p><p>&nbsp;</p><p>(CYP3A or P-gp induction)</p></td><td style="height:69.5pt; vertical-align:top; width:181.7pt"><p>Co-administration is contraindicated.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If ZEPATIER is co-administered with ribavirin, the information for ribavirin with regard to contraception, pregnancy testing, pregnancy, breast-feeding, and fertility also applies to this combination regimen (refer to the Summary of Product Characteristics for the co-administered medicinal product for additional information).</p><p>&nbsp;</p><p><u>Women of childbearing potential / contraception in males and females</u></p><p>When ZEPATIER is used in combination with ribavirin, women of childbearing potential or their male partners must use an effective form of contraception during treatment and for a period of time after the treatment has concluded.</p><p><strong>&nbsp;</strong></p><p><u>Pregnancy </u></p><p>There are no adequate and well-controlled studies with ZEPATIER in pregnant women. Animal studies do not indicate harmful effects with respect to reproductive toxicity. Because reproduction animal studies are not always predictive of human response, ZEPATIER should be used only if the potential benefit justifies the potential risk to the fetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether elbasvir or grazoprevir and their metabolites are excreted in human milk.</p><p>Available pharmacokinetic data in animals has shown excretion of elbasvir and grazoprevir in milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEPATIER therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of elbasvir and grazoprevir on fertility are available . Animal studies do not indicate harmful effects of elbasvir or grazoprevir on fertility at elbasvir and grazoprevir exposures higher than the exposure in humans at the recommended clinical dose (see section 5.3).</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zepatier (administered alone or in combination with ribavirin) is not likely to have an effect on the ability to drive and use machines. Patients should be informed that fatigue has been reported during treatment with Zepatier (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of Zepatier was assessed based on 3 placebo-controlled studies and 7 uncontrolled Phase 2 and 3 clinical studies in approximately 2,000 subjects with chronic hepatitis C infection with&nbsp; compensated liver disease (with or without cirrhosis).</p><p>&nbsp;</p><p>In clinical studies, the most commonly reported adverse reactions (greater than 10%) were fatigue and headache. Less than 1 % of subjects treated with ZEPATIER with or without ribavirin had serious adverse reactions (abdominal pain, transient ischaemic attack and anaemia). Less than 1 % of subjects treated with ZEPATIER with or without ribavirin permanently discontinued treatment due to adverse reactions. The frequency of serious adverse reactions and discontinuations due to adverse reactions in subjects with compensated cirrhosis were comparable to those seen in subjects without cirrhosis.</p><p>&nbsp;</p><p>When elbasvir/grazoprevir was studied with ribavirin, the most frequent adverse reactions to</p><p>elbasvir/grazoprevir + ribavirin combination therapy were consistent with the known safety profile of ribavirin.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions were identified in patients taking ZEPATIER without ribavirin for 12 weeks. The adverse reactions are listed below by body system organ class and frequency. Frequencies are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) or very rare (&lt; 1/10,000).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 3: Adverse reactions identified with ZEPATIER*</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.3pt; vertical-align:top; width:153.95pt"><p><strong>Frequency</strong></p></td><td style="border-color:black; height:13.3pt; vertical-align:top; width:4.25in"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.6pt; width:459.95pt"><p><em>Metabolism and nutrition disorders:</em></p></td></tr><tr><td style="border-color:black; height:13.3pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.3pt; vertical-align:top; width:4.25in"><p>decreased appetite</p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.2pt; width:459.95pt"><p><em>Psychiatric disorders:</em></p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.1pt; vertical-align:top; width:4.25in"><p>insomnia, anxiety, depression</p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.15pt; width:459.95pt"><p><em>Nervous system disorders:</em></p></td></tr><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:153.95pt"><p>Very common</p></td><td style="height:13.2pt; vertical-align:top; width:4.25in"><p>headache</p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.1pt; vertical-align:top; width:4.25in"><p>dizziness</p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.2pt; width:459.95pt"><p><em>Gastrointestinal disorders:</em></p></td></tr><tr><td style="border-color:black; height:25.8pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:25.8pt; vertical-align:top; width:4.25in"><p>nausea, diarrhoea, constipation, upper abdominal pain, abdominal pain, dry mouth, vomiting</p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.1pt; width:459.95pt"><p><em>Skin and subcutaneous tissue disorders:</em></p></td></tr><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.2pt; vertical-align:top; width:4.25in"><p>pruritus, alopecia</p></td></tr><tr><td colspan="2" style="background-color:#d9d9d9; border-color:black; height:13.1pt; width:459.95pt"><p><em>Musculoskeletal and connective tissue disorders:</em></p></td></tr><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.2pt; vertical-align:top; width:4.25in"><p>arthralgia, myalgia</p></td></tr><tr><td colspan="2" style="background-color:#e4e4e4; border-color:black; height:13.2pt; width:459.95pt"><p><em>General disorders and administration site conditions:</em></p></td></tr><tr><td style="border-color:black; height:13.1pt; vertical-align:top; width:153.95pt"><p>Very common</p></td><td style="height:13.1pt; vertical-align:top; width:4.25in"><p>fatigue</p></td></tr><tr><td style="border-color:black; height:13.2pt; vertical-align:top; width:153.95pt"><p>Common</p></td><td style="height:13.2pt; vertical-align:top; width:4.25in"><p>asthenia, irritability</p></td></tr></tbody></table><p>*Based on pooled data from patients treated with ZEPATIER for 12 weeks without ribavirin</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Laboratory abnormalities</em></p><p><em>&nbsp;</em></p><p>Changes in selected laboratory parameters are described in Table 4.</p><p>&nbsp;</p><p>Table 4: Selected treatment emergent laboratory abnormalities</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:39.5pt; vertical-align:top; width:3.15in"><p><strong>Laboratory Parameters</strong></p></td><td style="border-color:black; height:39.5pt; vertical-align:top; width:3.1in"><p><strong>ZEPATIER</strong><strong>*</strong></p><p><strong>N = 834 n (%)</strong></p></td></tr><tr><td style="border-color:black; height:13.55pt; vertical-align:top; width:3.15in"><p><strong>ALT </strong><strong>(IU/L)</strong></p></td><td style="height:13.55pt; vertical-align:top; width:3.1in"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:13.45pt; vertical-align:top; width:3.15in"><p>5.1-10.0 &times; ULN&dagger;&nbsp;(Grade 3)</p></td><td style="height:13.45pt; vertical-align:top; width:3.1in"><p>6 (0.7%)</p></td></tr><tr><td style="border-color:black; height:13.55pt; vertical-align:top; width:3.15in"><p>&gt;10.0 &times; ULN (Grade 4)</p></td><td style="height:13.55pt; vertical-align:top; width:3.1in"><p>6 (0.7%)</p></td></tr><tr><td style="border-color:black; height:13.45pt; vertical-align:top; width:3.15in"><p><strong>Total Bilirubin (mg/dL)</strong></p></td><td style="height:13.45pt; vertical-align:top; width:3.1in"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:14.05pt; vertical-align:top; width:3.15in"><p>2.6-5.0 &times; ULN (Grade 3)</p></td><td style="height:14.05pt; vertical-align:top; width:3.1in"><p>3 (0.4%)</p></td></tr><tr><td style="border-color:black; height:13.45pt; vertical-align:top; width:3.15in"><p>&gt;5.0 &times; ULN (Grade 4)</p></td><td style="height:13.45pt; vertical-align:top; width:3.1in"><p>0</p></td></tr></tbody></table><p>*Based on pooled data from patients treated with ZEPATIER for 12 weeks without ribavirin</p><p>&dagger;ULN: Upper limit of normal according to testing laboratory.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Serum Late ALT elevations</u></em></p><p><em>&nbsp;</em></p><p>During clinical studies with ZEPATIER with or without ribavirin, regardless of treatment duration,</p><p>&lt; 1 % (13/1,690) of subjects experienced elevations of ALT from normal levels to greater than 5 times the ULN, generally at or after treatment week 8 (mean onset time 10 weeks, range 6-12 weeks). These late ALT elevations were typically asymptomatic. Most late ALT elevations resolved with ongoing therapy with ZEPATIER or after completion of therapy (see section 4.4). The frequency of late ALT elevations was higher in subjects with higher grazoprevir plasma concentration (see sections 4.4, 4.5 and 5.2). The incidence of late ALT elevations was not affected by treatment duration. Cirrhosis was not a risk factor for late ALT elevations. Less than 1% of subjects treated with ZEPATIER with or without ribavirin experienced ALT elevations &gt;2.5 &ndash; 5 times the ULN during treatment; there were no treatment discontinuations due to these ALT elevations.</p><p><u>&nbsp;</u></p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>No data are available.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li><u>Saudi Arabia: </u></li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC), at SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><ul><li><u>Other GCC States: </u></li></ul><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human experience of overdose with Zepatier is limited. The highest dose of elbasvir was 200 mg once daily for 10 days, and a single dose of 800 mg. The highest dose of grazoprevir was 1,000 mg</p><p>once daily for 10 days, and a single dose of 1,600 mg. In these healthy volunteer studies, adverse</p><p>reactions were similar in frequency and severity to those reported in the placebo groups.</p><p>&nbsp;</p><p>In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of</p><p>adverse reactions and appropriate symptomatic treatment instituted.</p><p>&nbsp;</p><p>Hemodialysis does not remove elbasvir or grazoprevir .Elbasvir and grazoprevir are</p><p>not expected to be removed by peritoneal dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use; Direct-acting antiviral, ATC code: J05AX68</p><p><strong>&nbsp;</strong></p><p><u>Mechanism</u><u> </u><u>of Action</u></p><p>ZEPATIER combines two direct-acting antiviral agents with distinct mechanisms of action and nonoverlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.</p><p>&nbsp;</p><p>Elbasvir is an inhibitor of&nbsp; HCV NS5A , which is essential for viral RNA replication and virion assembly.</p><p>&nbsp;Grazoprevir is an inhibitor of&nbsp; HCV NS3/4A protease , which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical assay, grazoprevir inhibited the proteolytic activity of the recombinant NS3/4A protease enzymes from HCV genotypes 1a, 1b, 3 and 4a with IC50 values ranging from 4 to 690 pM.</p><p>&nbsp;</p><p><u>Antiviral Activity</u></p><p>The EC50 values of elbasvir and grazoprevir against full-length or chimeric replicons encoding NS5A or NS3 sequences from reference sequences and clinical isolates are presented in Table 5.</p><p>&nbsp;</p><p>Table 5: Activities of elbasvir and grazoprevir in GT1a, GT1b and GT4 reference sequences and clinical isolates in replicon cells</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>&nbsp;</p></td><td style="border-color:black; height:15.0pt; vertical-align:top; width:157.45pt"><p><strong>Elbasvir</strong></p></td><td style="border-color:black; height:15.0pt; vertical-align:top; width:2.25in"><p><strong>Grazoprevir</strong></p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p><strong>Reference</strong></p></td><td colspan="2" style="height:15.0pt; vertical-align:top; width:319.45pt"><p><strong>EC</strong><strong>50</strong><strong>&nbsp;</strong><strong>nM</strong></p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT1a (H77)</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.004</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.4</p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT1b (con 1)</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.003</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.5</p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT4 (ED43)</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.0003</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.3</p></td></tr><tr><td colspan="3" style="border-color:black; height:15.0pt; vertical-align:top; width:6.45in"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p><strong>Clinical Isolates</strong></p></td><td colspan="2" style="height:15.0pt; vertical-align:top; width:319.45pt"><p><strong>Median</strong><strong> </strong><strong>EC</strong><strong>50</strong><strong>&nbsp;</strong><strong>(range) nM</strong></p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT1a</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.005 (0.003 &ndash; 0.009)a</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.8 (0.4 &ndash; 5.1)d</p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT1b</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.009 (0.005 &ndash; 0.01)b</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.3 (0.2 &ndash; 5.9)e</p></td></tr><tr><td style="border-color:black; height:15.0pt; vertical-align:top; width:144.95pt"><p>GT4</p></td><td style="height:15.0pt; vertical-align:top; width:157.45pt"><p>0.0007 (0.0002 &ndash; 34)c</p></td><td style="height:15.0pt; vertical-align:top; width:2.25in"><p>0.2 (0.11 &ndash; 0.33)a</p></td></tr><tr><td colspan="3" style="border-color:black; height:15.0pt; vertical-align:top; width:6.45in"><p>Number of isolates tested: a=5, b=4, c=14, d=10, e=9</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Resistance</u></p><p>&nbsp;</p><p><em>In Cell Culture </em></p><p>HCV replicons with reduced susceptibility to elbasvir and grazoprevir have been selected in cell culture for genotypes 1a, 1b, and 4.</p><p>&nbsp;</p><p>For elbasvir, in HCV genotype 1a replicons, single NS5A substitutions Q30D/E/H/K/R, L31M/V, and Y93C/H/N reduced elbasvir antiviral activity by 6- to 2,000-fold. In genotype 1b replicons, single NS5A substitutions L31F, and Y93H reduced elbasvir antiviral activity by 17-fold. In genotype 4 replicons, single NS5A substitutions L30S, M31V, and Y93H reduced elbasvir antiviral activity by 3- to 23-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of elbasvir resistance-associated substitutions further reduced elbasvir antiviral activity.</p><p>&nbsp;</p><p>For grazoprevir, in HCV genotype 1a replicons, single NS3 substitutions D168A/E/G/S/V/ reduced grazoprevir antiviral activity by 2- to 81-fold.. In genotype 1b replicons, single NS3 substitutions F43S, A156S/T/V, and D168A/G/V reduced grazoprevir antiviral activity by 3- to 375-fold. In genotype 4 replicons, single NS3 substitutions D168A/V reduced grazoprevir antiviral activity by 110- to 320-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of grazoprevir resistance-associated substitutions further reduced grazoprevir antiviral activity.</p><p>&nbsp;</p><p><em>In Clinical Studies</em></p><p>In a pooled analysis of subjects treated with regimens containing elbasvir/grazoprevir or elbasvir + grazoprevir with or without ribavirin in Phase 2 and 3 clinical studies,, resistance analyses were conducted for 50 subjects who experienced virologic failure and had sequence data available (6 with on-treatment virologic failure, 44 with post-treatment relapse).</p><p>&nbsp;</p><p>Treatment-emergent substitutions observed in the viral populations of these subjects based on genotypes are shown in Table 6. Treatment-emergent substitutions were detected in both HCV drug targets in 23/37 (62%) genotype 1a, 1/8 (13%) genotype 1b, and 2/5 (40%) genotype 4.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table</strong><strong> </strong><strong>6 - Treatment-Emergent Amino Acid Substitutions in the Pooled Analysis of Zepatier</strong><strong> </strong><strong>with and without Ribavirin Regimens in Phase 2 and Phase 3 Clinical Trials</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:34.9pt; vertical-align:top; width:45.0pt"><p><strong>Target</strong></p></td><td style="border-color:black; height:34.9pt; vertical-align:top; width:171.0pt"><p><strong>Emergent</strong><strong> </strong><strong>Amino Acid Substitutions</strong></p></td><td style="border-color:black; height:34.9pt; vertical-align:top; width:74.3pt"><p><strong>Genotype</strong><strong> </strong><strong>1a</strong><strong> </strong><strong>N = 37</strong></p><p><strong>% (n)</strong></p></td><td style="border-color:black; height:34.9pt; vertical-align:top; width:74.3pt"><p><strong>Genotype</strong><strong> </strong><strong>1b</strong><strong> </strong><strong>N = 8</strong></p><p><strong>% (n)</strong></p></td><td style="border-color:black; height:34.9pt; vertical-align:top; width:74.15pt"><p><strong>Genotype</strong><strong> </strong><strong>4</strong></p><p><strong>N = 5</strong></p><p><strong>% (n)</strong></p></td></tr><tr><td style="border-color:black; height:62.8pt; vertical-align:top; width:45.0pt"><p>NS5A</p></td><td style="height:62.8pt; vertical-align:top; width:171.0pt"><p>Any of the following NS5A substitutions: M/L28A/G/T/S * Q30H/K/R/Y, L/M31F/M/I/V, H/P58D, Y93H/N/S</p></td><td style="height:62.8pt; vertical-align:top; width:74.3pt"><p>81% (30)</p></td><td style="height:62.8pt; vertical-align:top; width:74.3pt"><p>88% (7)</p></td><td style="height:62.8pt; vertical-align:top; width:74.15pt"><p>100% (5)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>M/L28A/G/T/S</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>19% (7)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>13% (1)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>60% (3)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>Q30H/K/Y</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>14% (5)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>Q30R</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>46% (17)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>L/M31M/F/I/V&dagger;</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>11% (4)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>25% (2)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>40% (2)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>H/P58D&Dagger;</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>5% (3)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>Y93H/N/S</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>14% (5)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>63% (5)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td style="border-color:black; height:46.45pt; vertical-align:top; width:45.0pt"><p>NS3</p></td><td style="height:46.45pt; vertical-align:top; width:171.0pt"><p>Any of the following NS3 substitutions: V36L/M, Y56F/H, V107I, R155I/K, A156G/M/T/V, V158A, D168A/C/E/G/N/V/Y, V170I</p></td><td style="height:46.45pt; vertical-align:top; width:74.3pt"><p>78% (29)</p></td><td style="height:46.45pt; vertical-align:top; width:74.3pt"><p>25% (2)</p></td><td style="height:46.45pt; vertical-align:top; width:74.15pt"><p>40% (2)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>V36L/M</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>11% (4)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>Y56F/H</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>14% (5)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>13% (1)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>V107I</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>3% (1)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>13% (1)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>R155I/K</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>5% (2)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>A156T</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>27% (10)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>13% (1)</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>A156G/V/M</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>8% (3)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>60% (3)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>V158A</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>5% (2)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>--</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>D168A</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>35% (13)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>D168C/E/G/N/V/Y</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>14% (5)</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td style="border-color:black; height:12.0pt; vertical-align:top; width:45.0pt"><p>&nbsp;</p></td><td style="height:12.0pt; vertical-align:top; width:171.0pt"><p>V170I</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.3pt"><p>--</p></td><td style="height:12.0pt; vertical-align:top; width:74.15pt"><p>20% (1)</p></td></tr><tr><td colspan="5" style="border-color:black; height:69.5pt; vertical-align:top; width:438.75pt"><p>*Reference sequences for NS5A at amino acid 28 are M (genotype 1a) and L (genotype 1b and genotype</p><p>4a and 4d).</p><p>&dagger;Reference sequences for NS5A at amino acid 31 are L (genotype 1a and genotype 1b) and M (genotype 4a and 4d).</p><p>&Dagger;Reference sequences for NS5A at amino acid 58 are H (genotype 1a) and P (genotype 1b and genotype 4a and 4d).</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;Cross Resistance</u></p><p>Elbasvir is active <em>in vitro </em>against genotype 1a NS5A substitutions, M28V and Q30L, genotype 1b substitutions, L28M/V, R30Q, L31V, Y93C, and genotype 4 substitution, M31V which confer resistance to other NS5A inhibitors. In general, other NS5A substitutions conferring resistance to NS5A inhibitors may also confer resistance to elbasvir. NS5A substitutions conferring resistance to elbasvir may reduce the antiviral activity of other NS5A inhibitors.</p><p>&nbsp;</p><p>Grazoprevir is active in vitro against the following genotype 1a NS3 substitutions which confer</p><p>resistance to other NS3/4A protease inhibitors: V36A/L/M, Q41R, F43L, T54A/S, V55A/I, Y56F,</p><p>Q80K/R, V107I, S122A/G/R/T, I132V, R155K, A156S, D168N/S, I170T/V. Grazoprevir is active in vitro against the following genotype 1b NS3 substitutions conferring resistance to other NS3/4A</p><p>protease inhibitors: V36A/I/L/M, Q41L/R, F43S, T54A/C/G/S, V55A/I, Y56F, Q80L/R, V107I,</p><p>S122A/G/R, R155E/K/N/Q/S, A156G/S, D168E/N/S, V170A/I/T. Some NS3 substitutions at A156 and at D168 confer reduced antiviral activity to grazoprevir as well as to other NS3/4A protease inhibitors. The substitutions associated with resistance to NS5B inhibitors are susceptible to elbasvir or grazoprevir.</p><p>&nbsp;</p><p><u>Persistence of Resistance-Associated Substitutions</u></p><p>The persistence of elbasvir and grazoprevir treatment-emergent amino acid substitutions in NS5A, and NS3, respectively, was assessed in genotype 1-infected subjects in Phase 2 and 3 studies whose virus had treatment-emergent resistance-associated substitution in the drug target, and with available data through at least 24 weeks post-treatment using population (or Sanger) sequencing.</p><p>&nbsp;</p><p>Viral populations with treatment-emergent NS5A resistance-associated substitutions were generally more persistent than NS3 resistance associated substitutions. Among genotype 1a-infected subjects,</p><p>NS5A resistance-associated substitutions persisted at detectable levels at follow-up week 12 in 95% (35/37) of subjects and in 100% (9/9) of subjects with follow-up week 24 data. Among genotype 1binfected subjects, NS5A resistance-associated substitutions persisted at detectable levels in 100% (7/7) of subjects at follow-up week 12 and in 100% (3/3) of subjects with follow-up week 24 data.</p><p>&nbsp;</p><p>Among genotype 1-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 31% (4/13) of subjects. Among genotype 1b-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 50% (1/2) of subjects.</p><p>&nbsp;</p><p>Due to the limited number of genotype 4-infected subjects with treatment-emergent NS5A and NS3 resistance-associated substitutions, trends in persistence of treatment-emergent substitutions in these genotypes could not be established.</p><p>&nbsp;</p><p>The long-term clinical impact of the emergence or persistence of virus containing ZEPATIER</p><p>resistance-associated substitutions is unknown.</p><p>&nbsp;</p><p><u>Effect of Baseline HCV Polymorphisms on Treatment Response</u></p><p>In pooled analyses of subjects who achieved SVR12 or met criteria for virologic failure, the</p><p>prevalence and impact of NS5A polymorphisms (including M28T/A, Q30E/H/R/G/K/D, L31M/V/F, H58D, and Y93C/H/N) and NS3 polymorphisms (substitutions at positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, and 175) that confer greater than 5-fold reduction of elbasvir and grazoprevir antiviral activity respectively in vitro were evaluated. The observed treatment response differences by treatment regimen in specific patient populations in the presence or absence of baseline NS5A or NS3 polymorphisms are summarised in Table 7.</p><p>&nbsp;</p><p>Table 7: SVR in GT1a-, GT1b- or treatment-experienced GT4-infected subjects bearing baseline NS5A or NS3 polymorphisms</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="border-color:black; height:13.55pt; vertical-align:top; width:1.2in"><p>&nbsp;</p></td><td colspan="4" style="border-color:black; height:13.55pt; vertical-align:top; width:373.55pt"><p><strong>SVR12 by Treatment Regimen</strong></p></td></tr><tr><td colspan="2" style="height:13.45pt; vertical-align:top; width:189.0pt"><p><strong>ZEPATIER, 12</strong><strong> Weeks</strong></p></td><td colspan="2" style="border-color:black; height:13.45pt; vertical-align:top; width:184.55pt"><p><strong>ZEPATIER </strong><strong>+ RBV, 16 Weeks</strong></p></td></tr><tr><td style="border-color:black; height:69.95pt; vertical-align:top; width:1.2in"><p><strong>&nbsp;</strong></p><p><strong>Patient Population</strong></p></td><td style="height:69.95pt; vertical-align:top; width:94.55pt"><p><strong>Subjects without</strong><strong> </strong><strong>baseline NS5A</strong><strong> </strong><strong>polymorphisms,</strong><strong>*</strong></p><p><strong>% (n/N)</strong></p></td><td style="height:69.95pt; vertical-align:top; width:94.45pt"><p><strong>Subjects with</strong><strong> </strong><strong>baseline NS5A polymorphisms,</strong><strong>*</strong></p><p><strong>% (n/N)</strong></p></td><td style="height:69.95pt; vertical-align:top; width:1.25in"><p><strong>Subjects without</strong><strong> </strong><strong>baseline NS5A</strong><strong> </strong><strong>polymorphisms,</strong><strong>*</strong></p><p><strong>% (n/N)</strong></p></td><td style="height:69.95pt; vertical-align:top; width:94.55pt"><p><strong>Subjects with</strong><strong> </strong><strong>baseline NS5A</strong><strong> </strong><strong>polymorphisms,</strong><strong>*</strong></p><p><strong>% (n/N)</strong></p></td></tr><tr><td style="border-color:black; height:26.5pt; vertical-align:top; width:1.2in"><p><strong>GT1a</strong>&dagger;</p></td><td style="height:26.5pt; vertical-align:top; width:94.55pt"><p>97% (464/476)</p></td><td style="height:26.5pt; vertical-align:top; width:94.45pt"><p>53% (16/30)</p></td><td style="height:26.5pt; vertical-align:top; width:1.25in"><p>100% (51/51)</p></td><td style="height:26.5pt; vertical-align:top; width:94.55pt"><p>100% (4/4)</p></td></tr><tr><td style="border-color:black; height:26.5pt; vertical-align:top; width:1.2in"><p><strong>GT1b</strong>&Dagger;</p></td><td style="height:26.5pt; vertical-align:top; width:94.55pt"><p>99% (259/260)</p></td><td style="height:26.5pt; vertical-align:top; width:94.45pt"><p>92% (36/39)</p></td><td colspan="2" style="height:26.5pt; vertical-align:top; width:184.55pt"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="border-color:black; height:13.55pt; vertical-align:top; width:459.95pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:52.45pt; vertical-align:top; width:1.2in"><p>&nbsp;</p></td><td style="height:52.45pt; vertical-align:top; width:94.55pt"><p><strong>Subjects without</strong><strong> </strong><strong>baseline NS3</strong><strong> </strong><strong>polymorphisms,</strong><strong>&para;</strong></p><p><strong>% (n/N)</strong></p></td><td style="height:52.45pt; vertical-align:top; width:94.45pt"><p><strong>Subjects with</strong><strong> </strong><strong>baseline</strong><strong> NS3 polymorphisms,</strong><strong>&para;</strong></p><p><strong>% (n/N)</strong></p></td><td rowspan="3" colspan="2" style="height:52.45pt; vertical-align:top; width:184.55pt"><p>&nbsp;</p></td></tr><tr><td style="height:13.0pt; vertical-align:top; width:1.2in"><p><strong>GT4</strong><strong> </strong>(treatment-</p></td><td style="height:13.0pt; vertical-align:top; width:94.55pt"><p>86%</p></td><td style="height:13.0pt; vertical-align:top; width:94.45pt"><p>100%</p></td></tr><tr><td style="border-color:black; height:13.55pt; vertical-align:top; width:1.2in"><p>experienced)♯</p></td><td style="height:13.55pt; vertical-align:top; width:94.55pt"><p>(25/29)</p></td><td style="height:13.55pt; vertical-align:top; width:94.45pt"><p>(7/7)</p></td></tr><tr><td colspan="5" style="border-color:black; height:13.45pt; vertical-align:top; width:459.95pt"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="height:14.25pt; vertical-align:top; width:459.95pt"><p><strong>*</strong>NS5A polymorphisms (conferring &gt; 5-fold potency loss to elbasvir) included M28T/A, Q30E/H/R/G/K/D,</p></td></tr><tr><td colspan="5" style="height:12.1pt; vertical-align:top; width:459.95pt"><p>L31M/V/F, H58D, and Y93C/H/N</p></td></tr><tr><td colspan="5" style="height:13.9pt; vertical-align:top; width:459.95pt"><p>&dagger;Overall prevalence of GT1a-infected subjects with baseline NS5A polymorphisms in the pooled analyses was</p></td></tr><tr><td colspan="5" style="height:12.15pt; vertical-align:top; width:459.95pt"><p>7% (55/825)</p></td></tr><tr><td colspan="5" style="height:13.85pt; vertical-align:top; width:459.95pt"><p>&Dagger;Overall prevalence of GT1b-infected subjects with baseline NS5A polymorphisms in the pooled analyses was</p></td></tr><tr><td colspan="5" style="height:12.15pt; vertical-align:top; width:459.95pt"><p>14% (74/540)</p></td></tr><tr><td colspan="5" style="height:13.9pt; vertical-align:top; width:459.95pt"><p><strong>&para;</strong>NS3 polymorphisms considered were any amino acid substitution at positions 36, 54, 55, 56, 80, 107, 122,</p></td></tr><tr><td colspan="5" style="height:12.1pt; vertical-align:top; width:459.95pt"><p>132, 155, 156, 158, 168, 170, and 175.</p></td></tr><tr><td colspan="5" style="height:13.9pt; vertical-align:top; width:459.95pt"><p>♯Overall prevalence of GT4-infected subjects with baseline NS3 polymorphisms in the pooled analyses was</p></td></tr><tr><td colspan="5" style="border-color:black; height:12.35pt; vertical-align:top; width:459.95pt"><p>19% (7/36)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Clinical efficacy and safety</u></p><p>The safety and efficacy of elbasvir/grazoprevir (co-administered as a fixed-dose combination;</p><p>EBR/GZR) or elbasvir + grazoprevir (co-administered as single agents; EBR + GZR) were evaluated in 8 clinical studies in approximately 2,000 subjects (see Table 8).</p><p>&nbsp;</p><p>Table 8: Studies conducted with ZEPATIER</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:51.1pt; vertical-align:top; width:87.1pt"><p><strong>Study</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:78.7pt"><p><strong>Population</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:100.9pt"><p><strong>Study Arms and</strong><strong> </strong><strong>Duration (Number of Subjects Treated)</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:197.65pt"><p><strong>Additional Study Details</strong></p></td></tr><tr><td style="border-color:black; height:95.9pt; vertical-align:top; width:87.1pt"><p>C-EDGE TN</p><p>(double-blind)</p></td><td style="height:95.9pt; vertical-align:top; width:78.7pt"><p>GT 1, 4, 6</p><p>TN with or without cirrhosis</p></td><td style="height:95.9pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR/GZR* for 12 weeks (N=316)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Placebo for 12 weeks (N=105)</p></td><td style="height:95.9pt; vertical-align:top; width:197.65pt"><p>Placebo-controlled study in which subjects were randomised in a 3:1 ratio to: EBR/GZR for 12 weeks (immediate treatment group [ITG]) or placebo for 12 weeks followed by open-label treatment with EBR/GZR for</p><p>12 weeks (deferred treatment group (DTG)).</p></td></tr><tr><td style="border-color:black; height:82.45pt; vertical-align:top; width:87.1pt"><p>C-EDGE COINFECTION</p><p>(open-label)</p></td><td style="height:82.45pt; vertical-align:top; width:78.7pt"><p>GT 1, 4, 6</p><p>TN with or without cirrhosis HCV/HIV-1</p><p>co-infection</p></td><td style="height:82.45pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR/GZR for 12 weeks (N=218)</p></td><td style="height:82.45pt; vertical-align:top; width:197.65pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:126.95pt; vertical-align:top; width:87.1pt"><p>C-SURFER</p><p>(double-blind)</p></td><td style="height:126.95pt; vertical-align:top; width:78.7pt"><p>GT 1</p><p>TN or TE with or without cirrhosis Chronic Kidney Disease</p></td><td style="height:126.95pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR* for 12 weeks (N=122)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Placebo for 12 weeks (N=113)</p></td><td style="height:126.95pt; vertical-align:top; width:197.65pt"><p>Placebo-controlled study in subjects with CKD Stage 4 (eGFR 15-29 mL/min/1.73 m2) or Stage 5 (eGFR &lt; 15 mL/min/1.73 m2), including subjects on hemodialysis, Subjects were randomised in a 1:1 ratio to one of the following treatment groups: EBR + GZR for 12 weeks (ITG) or placebo for 12 weeks followed by open-label treatment with EBR/GZR for 12 weeks (DTG). In addition, 11 subjects received open-label EBR + GZR for 12 weeks (intensive PK arm).</p></td></tr><tr><td style="border-color:black; height:182.4pt; vertical-align:top; width:87.1pt"><p>C-WORTHY</p><p>(open-label)</p></td><td style="height:182.4pt; vertical-align:top; width:78.7pt"><p>GT 1, 3</p><p>TN with or without cirrhosis TE Null Responder</p><p>with or without cirrhosis</p><p>TN HCV/HIV-</p><p>1 co-infection without cirrhosis</p></td><td style="height:182.4pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR* for 8, 12, or</p><p>18 weeks</p><p>(N=31, 136,</p><p>and 63, respectively)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR*</p><p>+ RBV&dagger; for 8, 12, or 18 weeks</p><p>(N=60, 152,</p><p>and 65, respectively)</p></td><td style="height:182.4pt; vertical-align:top; width:197.65pt"><p>Multi-arm, multi-stage study.</p><p>Subjects with GT 1b infection without cirrhosis were randomised in a 1:1 ratio to EBR + GZR with or without RBV for</p><p>8 weeks.</p><p>TN subjects with GT 3 infection without cirrhosis were randomised to EBR + GZR with RBV for 12 or 18 weeks.</p><p>TN subjects with GT 1 infection with or without cirrhosis (with or without HCV/HIV- 1 co-infection) or who were peg-IFN + RBV null responders, were randomised to EBR + GZR with or without RBV for 8, 12 or</p><p>18 weeks.</p></td></tr><tr><td style="border-color:black; height:112.55pt; vertical-align:top; width:87.1pt"><p>C-SCAPE</p><p>(open-label)</p></td><td style="height:112.55pt; vertical-align:top; width:78.7pt"><p>GT 4, 6</p><p>TN without cirrhosis</p></td><td style="height:112.55pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR* for 12 weeks (N=14)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR*</p><p>+ RBV&dagger; for 12 weeks (N=14)</p></td><td style="height:112.55pt; vertical-align:top; width:197.65pt"><p>Subjects were randomised in a 1:1 ratio to the study arms.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:51.1pt; vertical-align:top; width:87.1pt"><p><strong>Study</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:78.7pt"><p><strong>Population</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:100.9pt"><p><strong>Study Arms and</strong><strong> </strong><strong>Duration (Number of Subjects Treated)</strong></p></td><td style="border-color:black; height:51.1pt; vertical-align:top; width:197.65pt"><p><strong>Additional Study Details</strong></p></td></tr><tr><td style="border-color:black; height:163.2pt; vertical-align:top; width:87.1pt"><p>C-EDGE TE</p><p>(open-label)</p></td><td style="height:163.2pt; vertical-align:top; width:78.7pt"><p>GT 1, 4, 6</p><p>TE with or without cirrhosis, and with or without HCV/HIV-1</p><p>co-infection</p></td><td style="height:163.2pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR/GZR for 12 or 16 weeks (N=105 and 105, respectively)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR/GZR + RBV&dagger; for 12 or 16 weeks (N=104 and 106, respectively)</p></td><td style="height:163.2pt; vertical-align:top; width:197.65pt"><p>Subjects were randomised in a 1:1:1:1 ratio to the study arms.</p></td></tr><tr><td style="border-color:black; height:95.05pt; vertical-align:top; width:87.1pt"><p>C-SALVAGE</p><p>(open-label)</p></td><td style="height:95.05pt; vertical-align:top; width:78.7pt"><p>GT 1</p><p>TE with HCV protease inhibitor regimen&Dagger;&nbsp;with or without cirrhosis</p></td><td style="height:95.05pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR* + GZR*</p><p>+ RBV&dagger;&nbsp;for 12 weeks (N=79)</p></td><td style="height:95.05pt; vertical-align:top; width:197.65pt"><p>Subjects who had failed prior treatment with boceprevir, simeprevir, or telaprevir in combination with peg-IFN + RBV received EBR + GZR with RBV for 12 weeks.</p></td></tr><tr><td style="border-color:black; height:93.85pt; vertical-align:top; width:87.1pt"><p>C-EDGE COSTAR</p><p>(double-blind)</p></td><td style="height:93.85pt; vertical-align:top; width:78.7pt"><p>GT 1, 4, 6</p><p>TN with or without cirrhosis Opiate agonist therapy</p></td><td style="height:93.85pt; vertical-align:top; width:100.9pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->EBR/GZR for 12 weeks (N=201)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Placebo for 12 weeks (N=100)</p></td><td style="height:93.85pt; vertical-align:top; width:197.65pt"><p>Placebo-controlled study in which subjects were randomised in a 2:1 ratio to EBR/GZR for 12 weeks (ITG) or placebo for 12 weeks followed by open-label treatment with EBR/GZR for 12 weeks (DTG). Subjects were not excluded or discontinued from the trial based on a positive urine drug screen.</p></td></tr></tbody></table><p>GT = Genotype</p><p>TN = Treatment-Na&iuml;ve</p><p>TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [peg-IFN] with or without ribavirin (RBV) or were intolerant to prior therapy)</p><p>*EBR = elbasvir 50 mg; GZR = grazoprevir 100 mg; EBR/GZR = co-administered as a fixed-dose combination; EBR + GZR = co-administered as separate single agents</p><p>&dagger;RBV was administered at a total daily dose of 800 mg to 1,400 mg based on weight (see section 4.2)</p><p>&Dagger; Failed prior treatment with boceprevir, telaprevir, or simeprevir in combination with peg-IFN + RBV</p><p>&nbsp;</p><p>Sustained virologic response (SVR) was the primary endpoint in all studies and was defined as HCV RNA less than the lower limit of quantification (LLOQ: 15 HCV RNA IU/mL except in C-WORTHY and C-SCAPE [25 HCV RNA IU/mL]) at 12 weeks after the cessation of treatment (SVR12).</p><p>&nbsp;</p><p>Among genotype 1b/1other-infected subjects, the median age was 55 years (range: 22 to 82); 61% were male; 60 % were White; 20% were Black or African American; 6% were Hispanic or Latino; 82% were treatment-na&iuml;ve subjects; 18% were treatment-experienced subjects; mean body mass index was 26 kg/m2; 64 % had baseline HCV RNA levels greater than 800,000 IU/mL; 22 % had cirrhosis; 71% had non-C/C IL28B alleles (CT or TT); 18 % had HCV/HIV-1 co-infection.</p><p>&nbsp;</p><p>Treatment outcomes in genotype 1b-infected subjects treated with elbasvir/grazoprevir for 12 weeks are presented in Table 9.</p><p>&nbsp;</p><p>Table 9: SVR in genotype 1b&dagger;-infected subjects&para;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:220.8pt"><p><strong>Baseline Characteristics</strong></p></td><td style="border-color:black; height:16.7pt; vertical-align:top; width:243.6pt"><p><strong>SVR</strong></p></td></tr><tr><td style="border-color:black; height:17.65pt; vertical-align:top; width:220.8pt"><p>&nbsp;</p></td><td style="height:17.65pt; vertical-align:top; width:243.6pt"><p><strong>EBR with GZR for 12</strong><strong> </strong><strong>weeks (N </strong><strong>= 312)</strong></p></td></tr><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:220.8pt"><p>Overall SVR</p></td><td style="height:16.7pt; vertical-align:top; width:243.6pt"><p>96% (301/312)</p></td></tr><tr><td colspan="2" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>Outcome for subjects without SVR</p></td></tr><tr><td style="height:16.15pt; vertical-align:top; width:220.8pt"><p>On-treatment virologic failure*</p></td><td style="height:16.15pt; vertical-align:top; width:243.6pt"><p>0% (0/312)</p></td></tr><tr><td style="height:14.1pt; vertical-align:top; width:220.8pt"><p>Relapse</p></td><td style="height:14.1pt; vertical-align:top; width:243.6pt"><p>1% (4/312)</p></td></tr><tr><td style="border-color:black; height:15.7pt; vertical-align:top; width:220.8pt"><p>Other&Dagger;</p></td><td style="height:15.7pt; vertical-align:top; width:243.6pt"><p>2% (7/312)</p></td></tr><tr><td colspan="2" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>SVR by cirrhosis status</p></td></tr><tr><td style="height:18.55pt; vertical-align:top; width:220.8pt"><p>Non-cirrhotic</p></td><td style="height:18.55pt; vertical-align:top; width:243.6pt"><p>95% (232/243)</p></td></tr><tr><td style="border-color:black; height:16.0pt; vertical-align:top; width:220.8pt"><p>Cirrhotic</p></td><td style="height:16.0pt; vertical-align:top; width:243.6pt"><p>100% (69/69)</p></td></tr></tbody></table><p>&dagger;Includes four subjects infected with genotype 1 subtypes other than 1a or 1b.</p><p>&para;Includes subjects from C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE, C-WORTHY and C-SURFER.</p><p>*Includes subjects with virologic breakthrough.</p><p>&Dagger;Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</p><p>&nbsp;</p><p>Among genotype 1a-infected subjects, the median age was 54 years (range: 19 to 76); 71 % were male; 71 % were White; 22 % were Black or African American; 9% were Hispanic or Latino; 74% were treatment-na&iuml;ve subjects; 26% were treatment-experienced subjects; mean body mass index was 27 kg/m2; 75 % had baseline HCV RNA levels greater than 800,000 IU/mL; 23 % had cirrhosis; 72% had non-C/C IL28B alleles (CT or TT); 30 % had HCV/HIV-1 co-infection.</p><p>&nbsp;</p><p>Treatment outcomes in genotype 1a-infected subjects treated with elbasvir/grazoprevir for 12 weeks or elbasvir/grazoprevir with ribavirin for 16 weeks are presented in Table 10.</p><p>&nbsp;</p><p>Table 10: SVR in genotype 1a-infected subjects&para;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:185.05pt"><p><strong>Baseline Characteristics</strong></p></td><td colspan="2" style="border-color:black; height:16.7pt; vertical-align:top; width:279.35pt"><p><strong>SVR</strong></p></td></tr><tr><td style="border-color:black; height:48.85pt; vertical-align:top; width:185.05pt"><p>&nbsp;</p></td><td style="height:48.85pt; vertical-align:top; width:137.4pt"><p><strong>EBR with GZR 12 Weeks</strong></p><p><strong>N=519</strong></p></td><td style="height:48.85pt; vertical-align:top; width:141.95pt"><p><strong>EBR with GZR + RBV</strong></p><p><strong>16 Weeks N=58</strong></p></td></tr><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:185.05pt"><p>Overall SVR</p></td><td style="height:16.7pt; vertical-align:top; width:137.4pt"><p>93% (483/519)</p></td><td style="height:16.7pt; vertical-align:top; width:141.95pt"><p>95% (55/58)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>Outcome for subjects without SVR</p></td></tr><tr><td style="height:16.0pt; vertical-align:top; width:185.05pt"><p>On-treatment virologic failure*</p></td><td style="height:16.0pt; vertical-align:top; width:137.4pt"><p>1% (3/519)</p></td><td style="height:16.0pt; vertical-align:top; width:141.95pt"><p>0% (0/58)</p></td></tr><tr><td style="height:15.1pt; vertical-align:top; width:185.05pt"><p>Relapse</p></td><td style="height:15.1pt; vertical-align:top; width:137.4pt"><p>4% (23/519)</p></td><td style="height:15.1pt; vertical-align:top; width:141.95pt"><p>0% (0/58)</p></td></tr><tr><td style="border-color:black; height:18.6pt; vertical-align:top; width:185.05pt"><p>Other&Dagger;</p></td><td style="height:18.6pt; vertical-align:top; width:137.4pt"><p>2% (10/519)</p></td><td style="height:18.6pt; vertical-align:top; width:141.95pt"><p>5% (3/58)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>SVR by cirrhosis status</p></td></tr><tr><td style="height:18.55pt; vertical-align:top; width:185.05pt"><p>Non-cirrhotic</p></td><td style="height:18.55pt; vertical-align:top; width:137.4pt"><p>93% (379/408)</p></td><td style="height:18.55pt; vertical-align:top; width:141.95pt"><p>92% (33/36)</p></td></tr><tr><td style="border-color:black; height:16.25pt; vertical-align:top; width:185.05pt"><p>Cirrhotic</p></td><td style="height:16.25pt; vertical-align:top; width:137.4pt"><p>94% (104/111)</p></td><td style="height:16.25pt; vertical-align:top; width:141.95pt"><p>100% (22/22)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.7pt; vertical-align:top; width:6.45in"><p>SVR by presence of baseline NS5A resistance-associated polymorphisms&dagger;,&nbsp;&sect;</p></td></tr><tr><td style="height:16.3pt; vertical-align:top; width:185.05pt"><p>Absent</p></td><td style="height:16.3pt; vertical-align:top; width:137.4pt"><p>97% (464/476)</p></td><td style="height:16.3pt; vertical-align:top; width:141.95pt"><p>100% (51/51)</p></td></tr><tr><td style="border-color:black; height:15.5pt; vertical-align:top; width:185.05pt"><p>Present</p></td><td style="height:15.5pt; vertical-align:top; width:137.4pt"><p>53% (16/30)</p></td><td style="height:15.5pt; vertical-align:top; width:141.95pt"><p>100% (4/4)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.7pt; vertical-align:top; width:6.45in"><p>SVR by baseline HCV RNA</p></td></tr><tr><td style="height:16.3pt; vertical-align:top; width:185.05pt"><p>&lt;=800,000 IU/mL</p></td><td style="height:16.3pt; vertical-align:top; width:137.4pt"><p>98% (135/138)</p></td><td style="height:16.3pt; vertical-align:top; width:141.95pt"><p>100% (9/9)</p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:185.05pt"><p>&gt;800,000 IU/mL</p></td><td style="height:15.25pt; vertical-align:top; width:137.4pt"><p>91% (348/381)</p></td><td style="height:15.25pt; vertical-align:top; width:141.95pt"><p>94% (46/49)</p></td></tr></tbody></table><p>&para;Includes subjects from C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE, C-WORTHY and C-SURFER.</p><p>*Includes subjects with virologic breakthrough.</p><p>&Dagger;Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</p><p>&dagger;Includes subjects with baseline sequencing data and who either achieved SVR12 or met criteria for virologic failure.</p><p>&sect;GT1a NS5A polymorphisms: M28T/A, Q30E/H/R/G/K/D, L31M/V/F, H58D, and Y93C/H/N.</p><p>&nbsp;</p><p>Among genotype 4-infected subjects, the median age was 51 years (range: 28 to 75); 66 % were male; 88 % were White; 8 % were Black or African American; 11% were Hispanic or Latino; 77% were treatment-na&iuml;ve subjects; 23% were treatment-experienced subjects; mean body mass index was</p><p>25 kg/m2; 56 % had baseline HCV RNA levels greater than 800,000 IU/mL; 22 % had cirrhosis; 73% had non-C/C IL28B alleles (CT or TT); 40 % had HCV/HIV-1 co-infection.</p><p>&nbsp;</p><p>Treatment outcomes in genotype 4-infected subjects treated with elbasvir/grazoprevir for 12 weeks or elbasvir/grazoprevir with ribavirin for 16 weeks are presented in Table 11.</p><p>&nbsp;</p><p>Table 11: SVR in genotype 4-infected subjects&para;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:185.05pt"><p><strong>Baseline Characteristics</strong></p></td><td colspan="2" style="border-color:black; height:16.7pt; vertical-align:top; width:279.35pt"><p><strong>SVR</strong></p></td></tr><tr><td style="border-color:black; height:48.85pt; vertical-align:top; width:185.05pt"><p>&nbsp;</p></td><td style="height:48.85pt; vertical-align:top; width:137.4pt"><p><strong>EBR with GZR 12 Weeks</strong></p><p><strong>N=65</strong></p></td><td style="height:48.85pt; vertical-align:top; width:141.95pt"><p><strong>EBR with GZR + RBV</strong></p><p><strong>16 Weeks N=8</strong></p></td></tr><tr><td style="border-color:black; height:16.7pt; vertical-align:top; width:185.05pt"><p>Overall SVR</p></td><td style="height:16.7pt; vertical-align:top; width:137.4pt"><p>94% (61/65)</p></td><td style="height:16.7pt; vertical-align:top; width:141.95pt"><p>100% (8/8)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>Outcome for subjects without SVR</p></td></tr><tr><td style="height:15.15pt; vertical-align:top; width:185.05pt"><p>On-treatment virologic failure*</p></td><td style="height:15.15pt; vertical-align:top; width:137.4pt"><p>0% (0/65)</p></td><td style="height:15.15pt; vertical-align:top; width:141.95pt"><p>0% (0/8)</p></td></tr><tr><td style="height:15.95pt; vertical-align:top; width:185.05pt"><p>Relapse&dagger;</p></td><td style="height:15.95pt; vertical-align:top; width:137.4pt"><p>3% (2/65)</p></td><td style="height:15.95pt; vertical-align:top; width:141.95pt"><p>0% (0/8)</p></td></tr><tr><td style="border-color:black; height:18.6pt; vertical-align:top; width:185.05pt"><p>Other&Dagger;</p></td><td style="height:18.6pt; vertical-align:top; width:137.4pt"><p>3% (2/65)</p></td><td style="height:18.6pt; vertical-align:top; width:141.95pt"><p>0% (0/8)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.8pt; vertical-align:top; width:6.45in"><p>SVR by cirrhosis status</p></td></tr><tr><td style="height:18.55pt; vertical-align:top; width:185.05pt"><p>Non-cirrhotic&sect;</p></td><td style="height:18.55pt; vertical-align:top; width:137.4pt"><p>96% (51/53)</p></td><td style="height:18.55pt; vertical-align:top; width:141.95pt"><p>100% (4/4)</p></td></tr><tr><td style="border-color:black; height:16.25pt; vertical-align:top; width:185.05pt"><p>Cirrhotic</p></td><td style="height:16.25pt; vertical-align:top; width:137.4pt"><p>83% (10/12)</p></td><td style="height:16.25pt; vertical-align:top; width:141.95pt"><p>100% (4/4)</p></td></tr><tr><td colspan="3" style="border-color:black; height:16.7pt; vertical-align:top; width:6.45in"><p>SVR by baseline HCV RNA</p></td></tr><tr><td style="height:15.45pt; vertical-align:top; width:185.05pt"><p>&lt;=800,000 IU/mL&Dagger;</p></td><td style="height:15.45pt; vertical-align:top; width:137.4pt"><p>93% (27/29)</p></td><td style="height:15.45pt; vertical-align:top; width:141.95pt"><p>100% (3/3)</p></td></tr><tr><td style="border-color:black; height:16.1pt; vertical-align:top; width:185.05pt"><p>&gt;800,000 IU/mL&dagger;</p></td><td style="height:16.1pt; vertical-align:top; width:137.4pt"><p>94% (34/36)</p></td><td style="height:16.1pt; vertical-align:top; width:141.95pt"><p>100% (5/5)</p></td></tr></tbody></table><p>&para;Includes subjects from C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE and C-SCAPE.</p><p>*Includes subjects with virologic breakthrough.</p><p>&dagger;Both relapsers had baseline HCV RNA &gt;800,000 IU/mL</p><p>&Dagger;Both subjects who failed to achieve SVR for reasons other than virologic failure had baseline HCV RNA</p><p>&lt;=800,000 IU/mL.</p><p>&sect;Includes 1 subject with cirrhosis status of &ldquo;unknown&rdquo; in C-SCAPE.</p><p>&nbsp;</p><p><em>Clinical study in subjects with advanced chronic kidney disease with genotype </em><em>1 CHC infection</em></p><p>In the C-SURFER study, overall SVR was achieved in 94 % (115/122) of subjects receiving EBR + GZR for 12 weeks.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with ZEPATIER in one or more subsets of the paediatric populations in the treatment of chronic hepatitis C (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following administration of elbasvir/grazoprevir to HCV-infected subjects, elbasvir peak plasma concentrations occur at a median Tmax&nbsp;of 3 hours (range of 3 to 6 hours); grazoprevir peak plasma concentrations occur at a median Tmax&nbsp;of 2 hours (range of 30 minutes to 3 hours). For elbasvir, the absolute bioavailability is estimated to be 32%. For grazoprevir, the absolute bioavailability after a 200 mg single dose ranged from 15 &ndash; 27% and after multiple 200 mg doses ranged from 20 &ndash; 40%.</p><p>&nbsp;</p><p>Relative to fasting conditions, the administration of a single dose of elbasvir/grazoprevir with a high-fat (900 kcal, 500 kcal from fat) meal to healthy subjects resulted in decreases in elbasvir AUC0-inf and Cmax&nbsp;of approximately 11% and 15%, respectively, and increases in grazoprevir AUC0-inf and Cmax&nbsp;of approximately 1.5-fold and 2.8-fold, respectively. These differences in elbasvir and grazoprevir exposure are not clinically relevant; therefore, elbasvir/grazoprevir may be taken without regard to food.</p><p>&nbsp;</p><p>Elbasvir pharmacokinetics are similar in healthy subjects and HCV-infected subjects. Grazoprevir oral exposures are approximately 2-fold greater in HCV-infected subjects as compared to healthy subjects.</p><p>&nbsp;</p><p>Based on the population pharmacokinetic modeling in non-cirrhotic, HCV-infected subjects, the geometric mean steady-state elbasvir AUC0-24 and Cmax at 50 mg were 2,180 nM&bull;hr and 137 nM, respectively, and the geometric mean steady-state grazoprevir AUC0-24 and Cmax at 100 mg were 1,860 nM&bull;hr and 220 nM, respectively. Following once daily administration of elbasvir/grazoprevir to HCV-infected subjects, elbasvir and grazoprevir reached steady state within approximately 6 days.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Elbasvir and grazoprevir are extensively bound (&gt;99.9% and 98.8%, respectively) to human plasma proteins. Both elbasvir and grazoprevir bind to human serum albumin and a1-acid glycoprotein. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The geometric mean apparent terminal half-life (% geometric mean coefficient of variation) is approximately 24 (24%) hours at 50 mg elbasvir and approximately 31 (34%) hours at 100 mg grazoprevir and in HCV-infected subjects.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>Elbasvir and grazoprevir are partially eliminated by oxidative metabolism, primarily by CYP3A. No circulating metabolites of either elbasvir or grazoprevir were detected in human plasma.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Excretion</u></p><p>The primary route of elimination of elbasvir and grazoprevir is through feces with almost all</p><p>(&gt;90%) of radiolabeled dose recovered in feces compared to &lt;1% in urine.</p><p>&nbsp;</p><p>Linearity/non-linearity</p><p>Elbasvir pharmacokinetics were approximately dose-proportional over the range of 5-100 mg once daily. Grazoprevir pharmacokinetics increased in a greater than dose-proportional manner over the range of 10-800 mg once daily in HCV-infected subjects.</p><p>&nbsp;</p><p><u>Pharmacokinetics in Special</u><u> </u><u>Populations</u><u> </u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In non-HCV-infected subjects with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) who were not on dialysis, elbasvir and grazoprevir AUC values were increased by 86 % and 65 %, respectively, compared to non-HCV-infected subjects with normal renal function (eGFR &gt; 80 mL/min/1.73 m2). In non-HCV-infected subjects with dialysis-dependent, severe renal impairment, elbasvir and grazoprevir AUC values were unchanged compared to subjects with normal renal function. Concentrations of elbasvir were not quantifiable in the dialysate samples. Less than 0.5 % of grazoprevir was recovered in dialysate over a 4-hour dialysis session.</p><p>&nbsp;</p><p>In population pharmacokinetic analysis in HCV-infected patients, elbasvir and grazoprevir AUCs were 25 % and 10 % higher, respectively, in dialysis-dependent patients and 46 % and 40 % higher, respectively, in non-dialysis-dependent patients with severe renal impairment compared to elbasvir</p><p>and grazoprevir AUC in patients without severe renal impairment.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>In non-HCV-infected subjects with mild hepatic impairment (Child-Pugh A [CP-A], score of 5-6), elbasvir AUC0-inf&nbsp;was decreased by 40% and grazoprevir steady-state AUC0-24&nbsp;was increased 70 % compared to matched healthy subjects.</p><p>In non-HCV-infected subjects with moderate hepatic impairment (Child-Pugh B [CP-B], score of 7-9), and severe hepatic impairment (Child-Pugh C [CP-C], score of 10-15) elbasvir AUC decreased by 28 % and 12%, respectively, while the grazoprevir steady-state AUC0-24&nbsp;was increased 5-fold and 12-fold respectively, compared to matched healthy subjects (see sections 4.2 and 4.3).</p><p>&nbsp;</p><p>Population PK analyses of HCV-infected patients in Phase 2 and 3 studies demonstrated that grazoprevir steady-state AUC0-24&nbsp;increased by approximately 65 % in HCV-infected patients with compensated cirrhosis (all with CP-A) compared to HCV-infected non-cirrhotic patients, while elbasvir steady-state AUC was similar (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>The pharmacokinetics of elbasvir/grazoprevir in paediatric patients less than 18 years of age have not been established (see section 4.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 16 % and 45 % higher, respectively, in subjects &ge; 65 years of age compared to subjects less than 65 years of age. These changes are not clinically relevant; therefore, no dose adjustment of elbasvir/grazoprevir is recommended based on age (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Gender</em></p><p>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 50 % and 30 % higher, respectively, in females compared to males. These changes are not clinically relevant; therefore, no dose adjustment of elbasvir/grazoprevir is recommended based on sex (see section 4.4).</p><p>&nbsp;</p><p><em>Weight/BMI</em></p><p>In population pharmacokinetic analyses, there was no effect of weight on elbasvir pharmacokinetics. Grazoprevir AUC is estimated to be 15 % higher in a 53 kg subject compared to a 77 kg subject. This change is not clinically relevant for grazoprevir. Therefore, no dose adjustment of elbasvir/grazoprevir is recommended based on weight/BMI (see section 4.4).</p><p>&nbsp;</p><p><em>Race/Ethnicity</em></p><p>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 15 % and 50 % higher, respectively, for Asians compared to Whites. Population pharmacokinetics estimates of exposure of elbasvir and grazoprevir were comparable between Whites and Black/African Americans. These changes are not clinically relevant; therefore, no dose adjustment of elbasvir/grazoprevir is recommended based on race/ethnicity (see section 4.4).</p><p>&nbsp;</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety</p><p>pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development with grazoprevir or elbasvir. Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. Carcinogenicity studies for grazoprevir and elbasvir have not been conducted.</p><p>&nbsp;</p><p><u>Embryo fetal and post natal development</u></p><p>&nbsp;</p><p><em>Elbasvir</em></p><p>Elbasvir was given to rats and rabbits without eliciting adverse effects on embryofetal or post natal development at up to the highest doses tested (approximately 9- and 17-fold above human exposure in rats and rabbits, respectively). Elbasvir has been shown to cross the placenta in rats and rabbits.</p><p>Elbasvir was excreted into the milk of lactating rats with concentrations 4-fold that of the maternal plasma concentrations.</p><p><em>&nbsp;</em></p><p><em>Grazoprevir</em></p><p>Grazoprevir was given to rats and rabbits without eliciting adverse effects on embryofetal or post natal development at up to highest doses tested (approximately 79- and 39-fold above human exposure in rats and rabbits, respectively). Grazoprevir has been shown to cross the placenta in rats and rabbits.</p><p>Grazoprevir was excreted into the milk of lactating rats with concentrations &lt; 1-fold of the maternal plasma concentrations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, vitamin E polyethylene glycol succinate.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>carnauba wax, ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide and triacetin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep Zepatier in its original blister pack until you are ready to take it. Do not take the pills out of the original blister pack to store in another container such as a pill box. This is important because the pills are sensitive to moisture. The pack is designed to protect them.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store Zepatier below 30&deg;C. Protect from moisture</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packaged into a carton containing two (2) cardboard cards, each cardboard card containing (2) 7-count aluminium blisters sealed in a cardboard card for a total of 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder (MAH)
Merck Sharp & Dohme B.V.,
Waarderweg 39, 2031BN,
Haarlem, The Netherlands


Manufacturer:
Shering-Plough Labo NV
Industriepark 30 – Zone A
B-2220 Heist-op-den-Berg
Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>